<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
[X] Quarterly Report Under Section 13 or 15 (d) of the Securities Exchange Act
of 1934
For the Quarter ended March 31, 1999
or
[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
Commission File Number 000-14824
PLEXUS CORP.
(Exact name of registrant as specified in charter)
Wisconsin 39-1344447
(State of Incorporation) (IRS Employer Identification No.)
55 Jewelers Park Drive
Neenah, Wisconsin 54957-0156
(Address of principal executive offices)(Zip Code)
Telephone Number (920) 722-3451
(Registrant's telephone number, Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes X No
---- ----
As of May 11, 1999 there were 15,167,511 shares of Common Stock of the
Company outstanding.
<PAGE> 2
PLEXUS CORP.
TABLE OF CONTENTS
March 31, 1999 and 1998
<TABLE>
<CAPTION>
<S> <C>
PART I. FINANCIAL INFORMATION....................................................................................3
Item 1. Consolidated Financial Statements...............................................................3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS.................................................3
CONDENSED CONSOLIDATED BALANCE SHEETS...........................................................4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS.................................................5
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS............................................6
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations...........8
GENERAL.........................................................................................8
YEAR 2000 ISSUES...............................................................................11
RESULTS OF OPERATIONS..........................................................................13
LIQUIDITY AND CAPITAL RESOURCES................................................................15
Item 3. Quantitative and Qualitative Disclosures about Market Risk.....................................16
PART II - OTHER INFORMATION......................................................................................17
Item 4. Submission of Matters to a Vote of Security Holders............................................17
Item 5. Other Information..............................................................................17
Item 6. Exhibits and Reports on Form 8-K...............................................................17
SIGNATURE........................................................................................................18
</TABLE>
2
<PAGE> 3
PART I. FINANCIAL INFORMATION
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
PLEXUS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share data)
Unaudited
<TABLE>
<CAPTION>
THREE MONTHS ENDED SIX MONTHS ENDED
MARCH 31, MARCH 31,
------------------------------------------------------------------------
1999 1998 1999 1998
---- ---- ---- ----
<S> <C> <C> <C> <C>
Net sales $ 103,388 $ 97,689 $ 205,117 $ 193,594
Cost of sales 88,177 85,847 175,623 171,458
------------ ------------ ------------ ------------
Gross profit 15,211 11,842 29,494 22,136
Selling and administrative
expenses 5,402 4,870 10,499 9,064
------------ ------------ ------------ ------------
Operating income 9,809 6,972 18,995 13,072
Other income (expense):
Interest expense
(2) (3) (5) (7)
Other 478 203 853 311
------------ ------------ ------------ ------------
Income before income taxes 10,285 7,172 19,843 13,376
Income taxes 4,113 2,834 7,938 5,293
------------ ------------ ------------ ------------
Net income $ 6,172 $ 4,338 $ 11,905 $ 8,083
============ ============ ============ ============
Earnings per share:
Basic $ 0.41 $ 0.29 $ 0.79 $ 0.55
============ ============ ============ ============
Diluted $ 0.38 $ 0.28 $ 0.73 $ 0.51
============ ============ ============ ============
Weighted average shares outstanding:
Basic 15,079,918 14,742,509 14,984,335 14,769,438
============ ============ ============ ============
Diluted 16,300,995 15,723,493 16,199,999 15,966,573
============ ============ ============ ============
</TABLE>
See notes to condensed consolidated fiancial statements.
3
<PAGE> 4
PLEXUS CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
Unaudited
<TABLE>
<CAPTION>
MARCH 31, SEPTEMBER 30,
1999 1998
--------------------------------------------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 33,181 $ 23,195
Accounts receivable, net of allowance of $630
and $505, respectively 51,393 48,433
Inventories 41,700 44,303
Deferred income taxes 4,370 3,344
Prepaid expenses and other 4,766 1,976
-------- ---------
Total current assets 135,410 121,251
Property, plant and equipment, net 23,252 21,355
Other 1,173 1,059
-------- ---------
Total assets $159,835 $ 143,665
======== =========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt $ 10 $ 114
Accounts payable 36,705 36,948
Customer deposits 3,839 3,787
Accrued liabilities:
Salaries and wages 5,858 5,161
Other 5,402 6,945
-------- ---------
Total current liabilities 51,814 52,955
Long-term debt 147 152
Deferred income taxes 951 700
Other liabilities 645 519
Stockholders' equity:
Preferred stock $.01 par value, 5,000,000 shares authorized,
none issued or outstanding - -
Common stock, $.01 par value, 60,000,000 shares authorized,
15,149,764 and 14,830,689 issued, respectively 151 148
Additional paid-in capital 26,875 21,776
Retained earnings 79,252 67,920
Treasury stock, at cost, 0 and 28,944 shares, respectively - (505)
-------- ---------
106,278 89,339
-------- ---------
Total liabilities and stockholders' equity $159,835 $ 143,665
======== =========
</TABLE>
See notes to consolidated financial statements.
4
<PAGE> 5
PLEXUS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Unaudited
<TABLE>
<CAPTION>
SIX MONTHS ENDED
MARCH 31,
-----------------------------------
1999 1998
---- ----
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net income $ 11,905 $ 8,083
Adjustments to reconcile net income to net cash
flows from operating activities:
Depreciation and amortization 3,609 2,995
Deferred income taxes (775) (738)
Changes in assets and liabilities:
Accounts receivable (2,960) 2,106
Inventories 2,603 2,044
Prepaid expenses and other (2,790) (778)
Accounts payable (243) 476
Customer deposits 52 (23)
Accrued liabilities (846) (1,190)
Other (86) (769)
-------- --------
Cash flows provided by operating activities 10,469 12,206
-------- --------
CASH FLOWS FROM INVESTING ACTIVITIES
Payments for property, plant and equipment (5,486) (4,841)
Other 79 122
-------- --------
Cash flows used in investing activities (5,407) (4,719)
-------- --------
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on debt (109) (3,357)
Proceeds from exercise of stock options 1,944 425
Tax benefit from stock options exercised 2,876 3,690
Treasury stock purchased (1,159) (1,799)
Treasury stock reissued 1,372 655
-------- --------
Cash flows provided by (used in) financing activities 4,924 (386)
-------- --------
Net increase in cash and cash equivalents 9,986 7,101
-------- --------
Cash and cash equivalents:
Beginning of period 23,195 3,655
-------- --------
End of period $ 33,181 $ 10,756
======== ========
</TABLE>
See notes to condensed consolidated financial statements.
5
<PAGE> 6
PLEXUS CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED MARCH 31, 1999
NOTE 1 - BASIS OF PRESENTATION
The condensed consolidated financial statements included herein have
been prepared by the Company without audit and pursuant to the rules and
regulations of the United States Securities and Exchange Commission. In the
opinion of the Company, the financial statements reflect all adjustments, which
consist only of normal recurring adjustments, necessary to present fairly the
financial position of Plexus Corp. at March 31, 1999 and the results of
operations for the three months and six months ended March 31, 1999 and 1998 and
the cash flows for the same six month periods.
Certain information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted pursuant to the SEC rules and
regulations dealing with interim financial statements. However, the Company
believes that the disclosures made in the condensed consolidated financial
statements included herein are adequate to make the information presented not
misleading. It is suggested that these condensed consolidated financial
statements be read in conjunction with the financial statements and notes
thereto included in the Company's 1998 Annual Report.
The condensed consolidated balance sheet data at September 30, 1998 was
derived from audited financial statements, but does not include all disclosures
required by generally accepted accounting principles.
NOTE 2 - INVENTORIES
The major classes of inventories are as follows (in thousands):
<TABLE>
<CAPTION>
March 31, September 30,
1999 1998
---------- ------------
<S> <C> <C>
Assembly parts $24,466 $25,165
Work-in-process 15,920 18,089
Finished goods 1,314 1,049
------- -------
$41,700 $44,303
======= =======
</TABLE>
6
<PAGE> 7
NOTE 3 - EARNINGS PER SHARE
The following is a reconciliation of the amounts utilized in the
computation of basic and diluted earnings per share (in thousands except per
share amounts):
<TABLE>
<CAPTION>
Three Months Ended Six Months Ended
March 31, March 31,
----------------------- ------------------------
1999 1998 1999 1998
--------- ---------- --------- ---------
<S> <C> <C> <C> <C>
BASIC EARNINGS PER SHARE:
Net income $6,172 $4,338 $11,905 $8,083
====== ====== ======= ======
Weighted average shares outstanding 15,080 14,743 14,984 14,769
====== ====== ======= ======
BASIC EARNINGS PER SHARE $ 0.41 $ 0.29 $ 0.79 $ 0.55
====== ====== ======= ======
DILUTED EARNINGS PER SHARE:
Net income $6,172 $4,338 $11,905 $8,083
====== ====== ======= ======
Weighted average shares outstanding 15,080 14,743 14,984 14,769
Effect of dilutive securities:
Stock options 1,221 980 1,216 1,198
------ ------ ------- ------
Diluted weighted average shares outstanding 16,301 15,723 16,200 15,967
====== ====== ======= ======
DILUTED EARNINGS PER SHARE $ 0.38 $ 0.28 $ 0.73 $ 0.51
====== ====== ======= ======
</TABLE>
NOTE 4 - NEW ACCOUNTING PRINCIPLES
The Company is required to adopt the Statement of Financial Accounting
Standard ("SFAS") No. 131, "Disclosure about Segments of an Enterprise and
Related Information," in fiscal 1999. SFAS No. 131 is not required to be applied
to interim financial statements in the initial year of adoption. The Company is
also required to adopt the American Institute of Certified Public Accountants
Statement of Position 98-1, "Accounting for the Costs of Computer Software
Developed or Obtained for Internal Use," in fiscal 2000. The Company does not
believe the adoption of these statements will have a significant impact on its
financial position or results of operations.
NOTE 5 - PENDING ACQUISITION
On March 16, 1999, Plexus entered into an Agreement and Plan of Merger
with SeaMED Corporation (SeaMED) providing for the acquisition of SeaMED by
Plexus in a stock-for-stock merger transaction under which each share of SeaMED
Common Stock would be converted into 0.4 (subject to a maximum exchange rate of
0.4444) shares of Plexus Common Stock. The acquisition is subject to several
conditions, including the approval of SeaMED's shareholders. The acquisition is
expected to close late in the third or early in the fourth quarter of fiscal
1999 and will be accounted for as a pooling-of-interests. One-time merger
related costs are currently expected to be approximately $4 million.
7
<PAGE> 8
On March 16, 1999, the Plexus Corp. Board of Directors rescinded the
Company's stock buyback program in contemplation of the pending merger with
SeaMED. As of March 29, 1999, all treasury stock shares were reissued.
NOTE 6 - RECLASSIFICATIONS AND RESTATEMENTS
Certain amounts in prior years' condensed consolidated financial
statements have been reclassified to conform to the 1999 presentation.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
STATEMENT FOR PURPOSES OF THE "SAFE HARBOR" PROVISION OF THE PRIVATE SECURITIES
LITIGATION REFORM ACT OF 1995
Management's Discussion and Analysis of Financial Condition and Results
of Operations, with the exception of historical matters, contains
forward-looking statements (such as statements in the future tense and
statements including "believe", "expect", "intend", "plan", "look forward to",
"anticipate" and similar terms) are forward-looking statements that involve
risks and uncertainties. Actual results may differ materially from these
statements as a result of various factors, including those discussed in further
detail below (in particular "General").
GENERAL
Plexus Corp. is a contract service provider of design, manufacturing
and testing services to the electronics industry, headquartered in Neenah,
Wisconsin. Through its wholly owned subsidiaries, Plexus Technology Group, Inc.,
and Plexus Electronic Assembly Corporation, the Company provides product
realization services to original equipment manufacturers in the medical,
computer (primarily mainframes, servers and peripherals), industrial,
telecommunications and transportation electronics industries. The Company offers
a full range of services including product development and design, material
procurement and management, prototyping, assembly, testing, manufacturing, final
system box build and distribution.
The Company has operations in Wisconsin, Kentucky, North Carolina,
Minnesota and California. The Company expects to open a new engineering facility
in Colorado in May 1999. The Company continues to look for opportunities for
geographical expansion that will improve the Company's ability to provide
services to its customers.
On March 16, 1999, Plexus entered into an Agreement and Plan of Merger
with SeaMED Corporation (SeaMED) providing for the acquisition of SeaMED by
Plexus in a stock-for-stock merger transaction under which each share of SeaMED
Common Stock would be converted into 0.4 (subject to a maximum exchange rate of
0.4444) shares of Plexus Common Stock. The acquisition is subject to several
conditions, including the approval of SeaMED's shareholders. The acquisition is
expected to close late in the third or early in the fourth fiscal quarter of
1999 and will be accounted for as a pooling-of-interests. Additional risk
factors specific to SeaMED's
8
<PAGE> 9
business and its operations include financing issues associated with SeaMED's
emerging medical customers, Food and Drug Administration (FDA) requirements
associated with Class III and pre-market approval (PMA) medical devices designed
and manufactured by SeaMED, and the uncertainty of third party reimbursement
such as Medicare, private health insurance companies or health maintenance
organization by SeaMED's customers for the cost of their products.
Geographical expansion and growth by acquisition can have an effect on
the Company's operations. The successful operation of an acquired business,
including SeaMED, will require communication and cooperation among key managers,
along with the transition of customer relationships. There can be no assurance
that the Company will successfully manage the integration of new locations or
acquired operations, and the Company may experience certain inefficiencies that
could negatively impact the results of operations or the Company's financial
condition. Additionally, no assurance can be given that any past or future
acquisition by the Company, including that of SeaMED, will enhance the Company's
business.
The Company's contract manufacturing services are provided on either a
turnkey basis, where the Company procures certain or all of the materials
required for product assembly, or on a consignment basis, where the customer
supplies some, or occasionally all, materials necessary for product assembly.
Turnkey services include material procurement and warehousing, in addition to
manufacturing, and involve greater resource investment and inventory risk
management than consignment services. Turnkey manufacturing currently represents
almost all of the Company's sales. Turnkey sales typically generate higher net
sales and higher gross profit dollars with lower gross margin percentages than
consignment sales due to the inclusion of component costs, and related markup,
in the Company's net sales. However, a change in component costs can directly
impact the average selling price, gross margins and the Company's net sales, and
the Company has added risk of inventory management. Due to the nature of turnkey
manufacturing, the Company's quarterly and annual results are affected by the
level and timing of customer orders, fluctuations in materials costs, and the
degree of automation used in the assembly process.
Since a substantial portion of the Company's sales are derived from
turnkey manufacturing, net sales can be negatively impacted by component
shortages. Shortages of key electronic components which are provided directly
from customers or suppliers can cause manufacturing interruptions, customer
rescheduling issues, production downtime and production set-up and restart
inefficiencies. From time to time, allocations of components can be an integral
part of the electronics industry. While in general the marketplace for such
components has eased, allowing greater availability, key component shortage
issues can still occur with respect to specific industries or particular
components. In response to this dynamic environment, the Company has a corporate
procurement organization whose primary purpose is to create strong supplier
alliances to assure a steady flow of components at competitive prices and
mitigate shortages. Strategic relationships have been established with
international purchasing offices to improve shortage and pricing issues.
However, because of the limited number of suppliers for certain electronic
components and other supply and demand concerns, the Company can neither
eliminate component shortages nor determine the timing or impact of such
shortages on the
9
<PAGE> 10
Company's results. As a result, the Company's sales and profitability can be
affected from period to period.
Many of the industries for which the Company currently provides
electronic products are subject to rapid technological changes, product
obsolescence, increased competition, and pricing pressures. In both the three
and six months ending March 31, 1999 and in fiscal 1998, approximately 4 percent
of the Company's total sales were foreign, with less than 2 percent going into
the Southeast Asian market, which is currently experiencing unfavorable currency
and economic conditions. These and other factors which affect the industries or
the markets that the Company serves, and which affect any of the Company's major
customers in particular, could have a material adverse effect on the Company's
results of operations.
The Company has no long-term volume commitments from its customers, and
lead-times for customer orders and product-life cycles continue to contract.
Although the Company obtains firm purchase orders from its customers, they
typically do not make firm orders for delivery of products more than 30 to 90
days in advance. The Company does not believe that the backlog of expected
product sales covered by firm purchase orders is a meaningful measure of future
sales since orders may be canceled and volume levels can be changed or delayed
at any time. The timely replacement of delayed, canceled or reduced programs
with new business cannot be assured. Because of these and other factors, there
can be no assurance that the Company's historical sales growth rate will
continue. In addition, fixed costs may not be fully recovered as a result of
cancelled, delayed or reduced programs and therefore, could impact results of
operations. See "Results of Operations -- Net Sales" below for certain factors
affecting net sales to the Company's largest customers.
The Company believes that its growth has been achieved in significant
part by its approach to partnering with customers mainly through its product
design and development services coupled with the Company's strategy of focusing
on those customers with a long-term outsourcing strategy and a need for complex
products requiring the Company's sophisticated technology and engineering
capabilities. Approximately 15 to 20 percent of the Company's contract
manufacturing sales are a direct result of the product design and development
services. The Company intends to continue to leverage this aspect of its product
design and development services for continued growth in contract manufacturing
revenues. Currently, the design and development services are less than 10
percent of total sales. In order to achieve expanded sales growth, the Company
must continue to generate additional sales from existing customers from both
current and future programs, and must successfully market to new customers. The
Company must also successfully integrate and leverage its new, and any future,
regional product design centers into this strategy. In addition, the Company
must continue to attract and retain top quality product development engineers in
order to continue to expand its design and development services. Because of
these and other factors, there can be no assurance that the Company's historic
growth rate will continue.
10
<PAGE> 11
Start-up costs, the management of labor and equipment efficiencies for
new programs and new customers, and the need to estimate required resources in
advance can have an effect on the Company's gross margins. These factors can
negatively impact gross margins early on in the life cycle of new programs. In
addition, labor efficiency and equipment utilization rates ultimately achieved
and maintained by the Company for new and current programs impact the Company's
gross margins.
The Company operates in a highly competitive industry. The Company
faces competition from a number of domestic and foreign electronic manufacturing
services companies, some with financial and manufacturing resources greater than
the Company's. The Company also faces competition in the form of current and
prospective customers that have the capabilities to develop and manufacture
products internally. In order to remain a viable alternative, the Company must
continue to enhance its total engineering and manufacturing technologies.
Other factors that could adversely affect forward-looking statements
include the level of overall growth in the electronics industry, the Company's
ability to complete the SeaMED transaction and integrate acquired operations,
the Company's ability to maintain and expand its customer base, material cost
fluctuations and the adequate availability of components and related parts for
production, the effect of changes in average selling prices, the effect of
start-up costs related to new facilities, year 2000 compliance issues (including
those discussed below), the overall economic conditions, the impact of increased
competition and other factors and risks detailed herein and in the Company's
other Securities and Exchange Commission filings.
YEAR 2000 ISSUES
The Company has a corporate information technology organization whose
primary purpose is to ensure vision and direction of information systems to meet
internal and external needs. The Company must keep pace with rapid technological
developments in its management information systems and its production facilities
and equipment, and can experience costs and conversion difficulties in
connection with the implementation of new systems and processes. In addition,
like all other companies, the Company must assure that its computer and software
systems, and other machinery and systems that depend upon computer-driven
operations or which have embedded chips or micro-processors, are capable of
accurately functioning and accurately recognizing and processing data in the
year 2000 and beyond ("Year 2000 Compliant").
The Year 2000 issue is the result of computer programs being written
using two digits rather than four to define the applicable year. Any of the
Company's manufacturing, design and testing equipment, computer programs or
computer hardware that have date-sensitive software or embedded chips may
recognize a date using "00" as the year 1900 rather that the year 2000. This
could result in a system failure or miscalculations causing disruptions of
operations, including, among other things, a temporary inability to operate
equipment, process transactions or engage in similar normal business activities.
11
<PAGE> 12
The Company has developed a Year 2000 compliance strategy and
methodology to help assure the Company can continue to provide engineering and
manufacturing services in the year 2000 and beyond. The Company's A/S400
hardware and software system, which handles virtually all production data
processing and accounting, has been tested and documented to be Year 2000
compliant. Internal final compliancy approval was completed in December 1998.
The Company is targeting June 30, 1999 to be compliant on all other mission
critical items.
The Company's Year 2000 strategy defines focus teams responsible for
information systems including hardware and software; production and facility
equipment and systems; test equipment and software; engineering development
systems; component and inventory issues; customer and supplier issues; and third
party agents and extended enterprises. Each team will complete four phases to
assure Year 2000 compliance which include a complete inventory and risk
assessment of items or issues (risk assessment defined as mission critical, non
mission critical, or not date sensitive); a strategy plan including
contingencies or remediation; the actual conversion or remediation including
testing and documentation; and compliancy approval.
The first phase of the plan (inventory and risk assessment) was
completed in December of 1998. The overall strategy has been determined and the
initial contingency plans are in various stages of completion. The actual
conversion, remediation and testing has commenced and is expected to continue
through May 1999. Internal final compliancy approval is expected to be completed
by the end of June 1999. Final contingency plans are scheduled to be in place by
September 1999 for any remaining or unexpected items.
The Company believes the costs associated with the Year 2000 compliancy
plan will be mostly current internal labor expenses and are not expected to
materially increase. Costs to date have not been material, and future compliancy
costs have not been determined, but are not expected to be material. Other
non-Year 2000 efforts have not been materially delayed or impacted by Year 2000
compliancy plan initiatives. There can be no assurance that these estimates will
prove to be accurate and actual results could differ materially from those
currently anticipated.
The Company presently believes that the Year 2000 issue will not pose
significant operational problems for the Company. However, if all Year 2000
issues are not properly identified, or assessment, remediation and testing are
not effected timely with respect to Year 2000 problems that are identified,
there can be no assurance that the Year 2000 issue will not materially adversely
impact the Company's results of operations or adversely affect the Company's
relationships with customers, vendors or others. The most reasonably likely
worst case scenario could cause a production shut down in one or more
facilities. The Company has not yet completed a contingency plan for such
occurrence, but has included completion of a contingency plan in its Year 2000
planning as discussed above. In addition, there can be no assurance that one or
more of the Company's suppliers or customers will not have material Year 20000
compliance problems. There can be no assurance that the Year 2000 issues of
other entities will not have a material adverse impact on the Company's systems
or results of operations. Additionally, there can be no assurance that potential
future costs of defending and
12
<PAGE> 13
resolving claims, if any, will not have a material adverse impact on the
Company's results of operations.
RESULTS OF OPERATIONS
NET SALES
Net sales for the three months ended March 31, 1999, increased 6
percent to $103.4 million from $97.7 million for the same period in the prior
fiscal year. Sales for the six months ended March 31, 1999 increased 6 percent
to $205.1 million from $193.6 million in March 31, 1998. Unit volume sales were
strong; however, sales growth was impacted by industry-wide pressure on average
selling prices, component prices, and on the Company's continued decision to
move toward higher technology business. These factors are expected to continue.
Although there can be no assurances, the Company presently anticipates sales
volume to remain steady, subject to the development and timing of new customers
and new programs.
Sales increased by customer industry group, from the same period in the
prior fiscal year, for all groups except for computer and transportation. This
reflects the Company's ongoing migration toward a more attractive mix of
business, with strength in the networking/telecom and medical markets. The
Company has transitioned away from the more commodity-related
computer-peripheral and automotive markets. The Company continues its strategy
of shifting the business mix towards customers with a long-term outsourcing
strategy and a need for complex products requiring the Company's advanced
technology solutions and engineering capabilities. Sales for the quarter ending
March 31, 1999 and 1998, respectively, by industry were as follows:
Telecommunications 28 percent (12 percent), Medical 24 percent (21 percent),
Industrial 18 percent (18 percent), Computer 18 percent (33 percent),
Transportation 9 percent (14 percent), and Other 3 percent (2 percent).
Currently, the Company does not expect there will be any material changes in the
breakdown of its sales by industry in fiscal 1999 from the current fiscal
quarter.
The Company's largest customers for the quarter ending March 31, 1999
were Ascend Communications, Inc. (Ascend) and General Electric Company (GE)
which accounted for 17 percent and 13 percent of sales respectively. For the six
months ended March 31, 1999 sales to Ascend and GE were 15 percent and 13
percent of sales, respectively. The Company's largest customers for the
six-months ending March 31, 1998 were International Business Machines
Corporation and GE which each accounted for 12 percent of sales. No other
customers accounted for more than 10 percent of the Company's sales for the six
months ended March 31, 1999 or 1998. Sales to the Company's ten largest
customers accounted for 66 percent for the six months ended March 31, 1999
compared to 71 percent for the same period in fiscal 1998 and 70 percent for all
of fiscal 1998. These results reflect the Company's dedication to continue to
diversifying its customer base and decreasing its dependence on any particular
customer or customers. The Company remains dependent upon continued sales to
Ascend, GE, and its other
13
<PAGE> 14
significant customers. Any material change in orders from these or other
customers could have a material effect on the Company's results of operations.
GROSS PROFIT
Gross profit increased 33 percent to $29.5 million, for the six months
ended March 31, 1999 from $22.1 million for the same period in the prior fiscal
year. The gross margin for the six months ended March 31, 1999 and 1998, was
14.4 percent and 11.4 percent, respectively. The gross margin increased to 14.7
percent for the three months ended March 31, 1999 from 12.1 percent for the same
period in the prior fiscal year, compared to 12.6 percent for all of fiscal
1998. The increase in gross margin primarily reflects the shift in business mix
to leading-technology products and markets and continued operating efficiencies.
Most of the research and development conducted by the Company is paid
for by customers and is, therefore, included in cost of sales. Other research
and development is conducted by the Company, but is not specifically identified
as the Company believes such expenses are less than 1 percent of its total
sales.
The Company's gross margin also reflects a number of other factors
which can vary from period to period, including product mix, the level of
start-up costs and efficiencies of new programs, product life cycles, sales
volumes, capacity utilization of surface mount and other equipment, labor costs
and efficiencies, the management of inventories, component pricing and
shortages, average sales prices, the mix of turnkey and consignment business,
fluctuations and timing of customer orders, changing demand for customer's
products and competition within the electronics business. These and other
factors can cause variations in the Company's operating results. While the
Company's focus is on maintaining and expanding gross margins, there can be no
assurance that gross margins will not decrease in future periods.
SELLING AND ADMINISTRATIVE EXPENSES
Selling and administrative (S&A) expenses increased to $10.5 million,
or 5.1 percent of sales for the six months ended March 31, 1999, compared to
$9.1 million, or 4.7 percent of sales, for the comparable prior fiscal year
period. For the quarters ended March 31, 1999 and 1998, S&A expenses were $5.4
million, or 5.2 percent of sales, and $4.9 million, or 5.0 percent of sales,
respectively. The increase in expenses was mainly attributable to increased
engineering, sales and marketing, and information systems support. The Company
anticipates future S&A expenses will increase in absolute dollars but remain
steady at approximately 5 percent of sales, as the Company continues to expand
these support areas. The Company will have one-time merger related expenses
associated with the acquisition of SeaMED at the time of closing.
14
<PAGE> 15
INCOME TAXES
Income taxes increased to $4.1 million and $7.9 million for the three
and six months ended March 31, 1999 compared to $2.8 million and $5.3 million in
the comparable period in fiscal 1998, as a result of increased earnings. The
Company's effective income tax rate has remained constant at rates between 39
percent to 40 percent. These rates approximate the blended Federal and state
statutory rate as a result of the Company's operations being located within the
United States.
LIQUIDITY AND CAPITAL RESOURCES
Cash flows from operating activities were $10.5 million for the six
months ended March 31, 1999 compared to $12.2 million in the comparable period
in fiscal 1998. The decrease in cash from operations was a result of increased
net income offset by changes in accounts receivables and prepaid expenses
compared to the prior fiscal year. Annualized inventory turnover improved to
8.2 turns as of March 31, 1999, from 7.3 turns as of March 31, 1998 and from 7.5
turns for all of fiscal 1998.
Cash flows used in investing activities totaled $5.4 million and was
utilized primarily to purchase additional manufacturing equipment.
The Company utilizes available cash, debt and operating leases to fund
its manufacturing equipment needs. The Company utilizes operating leases
primarily in situations where technical obsolescence concerns are determined to
outweigh the benefits of financing the equipment purchase. The Company estimates
that capital expenditures for fiscal 1999 to be similar to fiscal 1998 at
approximately $10 to $12 million, which the Company expects to fund through cash
flows from operations and, if needed, its $40 million long-term revolving credit
agreement.
Cash flows provided by financing activities totaled $4.9 million for
the six months ended March 31, 1999, primarily representing the proceeds and tax
benefit from the exercise of stock options. There have been no borrowings under
the Company's revolving credit agreement since October 1, 1997. The ratio of
total debt-to-equity as of March 31, 1999 and September 30, 1998 was 0.5 to 1
and 0.6 to 1, respectively.
The Company's future needs for financial resources include increases in
working capital to support anticipated sales growth and investment in
manufacturing and engineering facilities and equipment. However, because of the
dynamics of the Company's industry, the exact timing and amount of increases in
working capital cannot be determined. Currently, the Company anticipates
incurring future facility related expenditures in connection with the expansion
of its engineering headquarters in Neenah, Wisconsin and additional regional
engineering facilities.
Working capital was $83.6 million at March 31, 1999 and $68.3 million
at September 30, 1998. The Company has and will continue to evaluate
geographical expansion and growth by acquisition.
15
<PAGE> 16
The Company believes that its $40 million long-term revolving credit
agreement, leasing capabilities and projected cash from operations will be
sufficient to meet its working capital and capital requirements through fiscal
1999 and the foreseeable future. While there can be no assurance that future
financing will be available on terms acceptable to the Company, the Company may
seek to raise additional capital through the issuance of either public or
private debt or equity securities. Debt financing may require the Company to
pledge assets as collateral and comply with certain financial ratios and
covenants. Equity financing may result in dilution to stockholders.
The Company has not paid dividends on its common stock, but has
reinvested its earnings to support its working capital and expansion
requirements. The Company intends to continue to utilize its earnings in the
development and expansion of the business and does not expect to pay cash
dividends in the foreseeable future.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The following discussion about the Company's risk-management activities
may include forward-looking statements that involve risk and uncertainties.
Actual results could differ materially from those discussed.
The Company has financial instruments, including short-term cash
investments and long-term debt, which are sensitive to changes in interest
rates. However, the Company currently does not use any interest-rate swaps or
other types of derivative financial instruments to limit its sensitivity to
changes in interest rates because of the relatively short-term nature of its
cash investments and immaterial amount of its long-term debt.
The Company does not believe there has been any material changes in the
reported market risks faced by the Company since the end of its most recent
quarter March 31, 1999.
16
<PAGE> 17
PART II - OTHER INFORMATION
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
At the Company's annual meeting of shareholders on March 3, 1999, the
seven continuing directors who were management's nominees for re-election were
re-elected. The nominees/directors were re-elected with the following votes:
<TABLE>
<CAPTION>
Authority for
Director's Name Votes "For" Voting Withheld
- --------------- ----------- ---------------
<S> <C> <C>
David J. Drury 14,091,377 32,156
Harold R. Miller 14,120,238 3,295
John L. Nussbaum 14,115,529 8,004
Gerald A. Pitner 14,106,380 17,153
Thomas J. Prosser 14,122,905 628
Peter Strandwitz 14,117,532 6,001
Jan VerHagen 14,094,057 29,476
</TABLE>
ITEM 5. OTHER INFORMATION
The Company has been named as a defendant in The Oneida Tribe of
Indians of Wisconsin vs. Plexus Corp., filed in Wisconsin Circuit Court for
Brown County on April 9, 1999. The suit claims that the Company misrepresented
the potential profitability of the Green Bay facility built by Oneida Nation
Electronics, a tribally chartered corporation, and operated by the Company. The
Company believes that the claims are without merit, and intends to defend the
action vigorously. The Company has chosen to provide information about this
matter even though it does not believe that the claim is material to the
Company.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
Exhibit 2.1 - Agreement and Plan of Merger
dated March 16, 1999 among the
Company, PS Acquisition Corp. and
SeaMED Corporation.
Exhibit 27 - Financial Data Schedule
(b) Reports on Form 8-K
None
17
<PAGE> 18
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant had duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
5/13/99 /s/ Peter Strandwitz
------- ------------------------------
Date Peter Strandwitz
Chairman and CEO
(Principal Executive Officer)
5/13/99 /s/ Thomas B. Sabol
------- ------------------------------
Date Thomas B. Sabol
Vice President-Finance &
Chief Financial Officer
(Principal Financial Officer)
18
<PAGE> 1
AGREEMENT AND PLAN OF MERGER
BY AND AMONG
PLEXUS CORP.
AND
SEAMED CORPORATION
AND
PS ACQUISITION CORP.
DATED AS OF MARCH 16TH, 1999
<PAGE> 2
TABLE OF CONTENTS
<TABLE>
<S> <C>
RECITALS.......................................................................................................1
ARTICLE I DEFINITIONS.........................................................................................1
Acquisition...........................................................................................1
Affiliates............................................................................................2
Affiliate Letter......................................................................................2
Agreement.............................................................................................2
Articles of Merger....................................................................................2
Closing...............................................................................................2
Closing Date..........................................................................................2
Code..................................................................................................2
Confidentiality Agreement.............................................................................2
Disclosure Schedule...................................................................................2
ERISA.................................................................................................2
Employee Stock Purchase Plan..........................................................................2
Exchange Act..........................................................................................3
HSR Act...............................................................................................3
Knowledge of Parent...................................................................................3
Knowledge of Target...................................................................................3
Law...................................................................................................3
Merger................................................................................................3
Person................................................................................................3
Parent................................................................................................3
Parent Common Stock...................................................................................3
Parent Companies......................................................................................3
Parent Material Adverse Effect........................................................................3
Parent Stock Value....................................................................................4
Proxy Statement.......................................................................................4
Registration Statement................................................................................4
Rights Agreement......................................................................................4
Target................................................................................................4
Target Common Stock...................................................................................4
Target Material Adverse Effect........................................................................4
Target Rights.........................................................................................4
Target Special Meeting................................................................................4
Target Stockholders...................................................................................4
SEC...................................................................................................4
Securities Act........................................................................................5
Subsidiary............................................................................................5
Voting Agreements.....................................................................................5
WBCA..................................................................................................5
Year 2000 Compliant...................................................................................5
Other Terms...........................................................................................5
</TABLE>
-i-
<PAGE> 3
<TABLE>
<S> <C>
ARTICLE II THE MERGER.........................................................................................7
2.1 The Merger...................................................................................7
2.2 Effective Time of Merger.....................................................................7
2.3 Articles of Incorporation of Surviving Corporation...........................................7
2.4 Bylaws of Surviving Corporation..............................................................7
2.5 Directors and Officers of Surviving Corporation..............................................7
2.6 Conversion of Target Common Stock............................................................7
2.7 Conversion of Acquisition Common Stock.......................................................8
2.8 Exchange of Target Certificates..............................................................8
2.9 Stock Transfer Books........................................................................11
2.10 Reorganization; Pooling.....................................................................11
2.11 Dissenting Shares...........................................................................11
2.12 Target Stock Options........................................................................11
2.13 Voting Agreements...........................................................................12
ARTICLE III OTHER AGREEMENTS.................................................................................12
3.1 Proxy Statement and Registration Statement..................................................12
3.2 Approval of Target Stockholders.............................................................12
3.3 HSR Act.....................................................................................13
3.4 Access......................................................................................13
3.5 Disclosure Schedule.........................................................................13
3.6 Conditions to Merger........................................................................14
3.7 Deliveries of Information; Consultation.....................................................14
3.8 Affiliates; Accounting and Tax Treatment....................................................15
3.9 Other Transactions..........................................................................15
3.10 Letter of Target's Accountants..............................................................18
3.11 Letter of Parent's Accountants..............................................................18
3.12 NASDAQ Listing..............................................................................19
3.13 Public Announcements........................................................................19
3.14 Indemnification and Insurance...............................................................19
3.15 Agreement of Parent.........................................................................20
3.16 Operation of Subsidiary; Relocation of Facilities..........................................20
3.17 Employee Benefits...........................................................................21
3.18 Severance Benefits..........................................................................21
3.19 Combined Financial Results..................................................................21
3.20 S-3 Registration............................................................................21
3.21 Additional Board Actions....................................................................22
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF TARGET..........................................................22
4.1 Organization; Business......................................................................22
4.2 Capitalization..............................................................................22
4.3 Authorization; Enforceability...............................................................23
4.4 No Violation or Conflict....................................................................23
4.5 Title to Assets.............................................................................23
4.6 Litigation..................................................................................23
4.7 Target SEC Reports and Books and Records....................................................24
</TABLE>
-ii-
<PAGE> 4
<TABLE>
<S> <C>
4.8 Absence of Certain Changes..................................................................24
4.9 Existing Contracts..........................................................................24
4.10 Performance of Existing Contracts...........................................................25
4.11 Insurance Policies..........................................................................26
4.12 Employee Benefit Plans......................................................................26
4.13 No Violation of Law.........................................................................27
4.14 Brokers.....................................................................................27
4.15 Taxes.......................................................................................28
4.16 Governmental Approvals......................................................................28
4.17 No Pending Other Transactions...............................................................29
4.18 Labor Matters...............................................................................29
4.19 Disclosure..................................................................................29
4.20 Information Supplied........................................................................29
4.21 Vote Required...............................................................................29
4.22 Accounting Matters..........................................................................30
4.23 Opinion of Financial Advisor................................................................30
4.24 Environmental Protection....................................................................30
4.25 Year 2000 Compliance........................................................................32
4.26 Customers...................................................................................33
4.27 Software Licenses...........................................................................33
4.28 Additional Board Approvals..................................................................33
ARTICLE V REPRESENTATIONS AND WARRANTIES OF PARENT AND ACQUISITION..........................................33
5.1 Organization................................................................................33
5.2 Capitalization..............................................................................33
5.3 Authorization; Enforceability...............................................................34
5.4 No Violation or Conflict....................................................................34
5.5 Litigation..................................................................................34
5.6 Parent SEC Reports..........................................................................34
5.7 Brokers.....................................................................................35
5.8 Governmental Approvals......................................................................35
5.9 Disclosure..................................................................................35
5.10 Information Supplied........................................................................35
5.11 Accounting Matters..........................................................................36
5.12 Absence of Certain Changes..................................................................36
5.13 No Violation of Law.........................................................................36
5.14 Year 2000 Compliance........................................................................36
5.15 Customers...................................................................................36
ARTICLE VI CONDUCT OF BUSINESS BY TARGET PENDING THE MERGER.................................................37
6.1 Carry on in Regular Course..................................................................37
6.2 Use of Assets...............................................................................37
6.3 No Default..................................................................................37
6.4 Employment Matters..........................................................................37
6.5 Indebtedness................................................................................37
</TABLE>
-iii-
<PAGE> 5
<TABLE>
<S> <C>
6.6 Preservation of Relationships...............................................................37
6.7 Compliance with Laws........................................................................37
6.8 Taxes.......................................................................................37
6.9 Amendments..................................................................................37
6.10 Dividends; Redemptions; Issuance of Stock...................................................38
6.11 No Dispositions or Acquisitions.............................................................38
ARTICLE VII CONDITIONS PRECEDENT TO THE OBLIGATIONS OF PARENT AND ACQUISITION...............................38
7.1 Compliance with Agreement...................................................................38
7.2 No Litigation...............................................................................38
7.3 Representations and Warranties of Target....................................................39
7.4 No Target Material Adverse Effect...........................................................39
7.5 Approval of Target Shareholders; Articles of Merger.........................................39
7.6 Closing Certificate.........................................................................39
7.7 Governmental Approvals......................................................................39
7.8 Accountant Letter...........................................................................39
7.9 Pooling Opinion.............................................................................39
7.10 Affiliate Letters...........................................................................40
7.11 Parent Stock Value..........................................................................40
7.12 Confidentiality Agreement...................................................................40
7.13 Target Rights and Approval..................................................................40
7.14 Dissenters..................................................................................40
7.15 Consents....................................................................................40
ARTICLE VIII CONDITIONS PRECEDENT TO THE OBLIGATIONS OF TARGET..............................................40
8.1 Compliance with Agreement...................................................................40
8.2 No Litigation...............................................................................40
8.3 Representations and Warranties of Parent and Acquisition....................................40
8.4 No Parent Material Adverse Effect...........................................................41
8.5 Approval of Target Stockholders; Articles of Merger.........................................41
8.6 Closing Certificate.........................................................................41
8.7 Governmental Approvals......................................................................41
8.8 Tax Opinion.................................................................................41
8.9 Accountant Letter...........................................................................41
8.10 Parent Stock Value..........................................................................42
ARTICLE IX TERMINATION; MISCELLANEOUS........................................................................42
9.1 Termination.................................................................................42
9.2 Rights on Termination; Waiver...............................................................43
9.3 Survival of Representations, Warranties and Covenants.......................................43
9.4 Entire Agreement; Amendment.................................................................43
9.5 Expenses....................................................................................44
9.6 Governing Law...............................................................................44
9.7 Assignment..................................................................................44
9.8 Notices.....................................................................................44
</TABLE>
-iv-
<PAGE> 6
<TABLE>
<S> <C>
9.9 Counterparts; Headings......................................................................45
9.10 Interpretation..............................................................................45
9.11 Severability................................................................................46
9.12 No Reliance.................................................................................46
9.13 Exhibits and Disclosure Schedule............................................................46
9.14 Further Assurances..........................................................................46
</TABLE>
EXHIBITS:
A. Form of Plexus Affiliate Letter
B. Form of SeaMED Affiliate Letter
C. Form of Employment Agreement
D. Form of Voting Agreement
-v-
<PAGE> 7
AGREEMENT AND PLAN OF MERGER
THIS AGREEMENT AND PLAN OF MERGER is made as of the 16TH day of March,
1999 by and among PLEXUS CORP., SEAMED CORPORATION and PS ACQUISITION CORP.
RECITALS
WHEREAS, the respective Boards of Directors of Plexus, SeaMED and
Acquisition have: (a) determined that the merger of Acquisition with and into
SeaMED pursuant to, and subject to all of the terms and conditions of, this
Agreement is advisable, fair and in the best interests of Plexus, SeaMED and
Acquisition and their respective shareholders; and (b) approved the Merger, this
Agreement and the transactions contemplated by this Agreement; and
WHEREAS, the Board of Directors of SeaMED has directed that this
Agreement and the transactions described in this Agreement be submitted for
approval at the SeaMED Special Meeting; and
WHEREAS, the Board of Directors of Plexus has directed that Plexus
Common Stock be issued pursuant to this Agreement; and
WHEREAS, Plexus, SeaMED and Acquisition desire to make certain
representations, warranties, covenants and agreements in connection with the
Merger; and
WHEREAS, Plexus, SeaMED and Acquisition intend, by executing this
Agreement, to adopt a plan of reorganization within the meaning of Section 368
of the Code and to cause the Merger to qualify as a reorganization under the
provisions of Sections 368(a) of the Code; and
WHEREAS, for financial accounting purposes, Plexus, SeaMED and
Acquisition intend that the Merger be accounted for as a pooling of interests.
NOW, THEREFORE, in consideration of the Recitals and of the mutual
covenants, conditions and agreements set forth herein and for other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, it is hereby agreed that:
ARTICLE I
DEFINITIONS
When used in this Agreement, the following terms shall have the meanings
specified:
Acquisition. "Acquisition" shall mean PS Acquisition Corp., a
Washington corporation and a wholly-owned Subsidiary of Plexus.
<PAGE> 8
Affiliates. "Affiliates" shall mean all Persons who are affiliates of
either SeaMED or Plexus for purposes of Rule 145 under the Securities Act or
Accounting Series Releases 130 and 135 of the SEC, or both.
Affiliate Letter. "Affiliate Letter" shall mean a letter from each
Affiliate in substantially the form of Exhibit A attached to this Agreement for
Affiliates of Plexus and Exhibit B for Affiliates of SeaMED.
Agreement. "Agreement" shall mean this Agreement and Plan of Merger,
together with the Exhibits attached hereto and together with the Disclosure
Schedule, as the same may be amended from time to time in accordance with the
terms hereof.
Articles of Merger. "Articles of Merger" shall mean Articles of Merger
in a form approved for filing in accordance with the WBCA.
Closing. "Closing" shall mean the conference to be held at 10:00 A.M.,
Central Time, on the Closing Date at the offices of Quarles & Brady LLP, 411
East Wisconsin Avenue, Milwaukee, Wisconsin 53202, or such other time and place
as the parties may mutually agree to in writing, at which the transactions
contemplated by this Agreement shall be consummated.
Closing Date. "Closing Date" shall mean:
(a) that date which is no more than two (2) business days
after satisfaction or waiver of all of the conditions set forth in Article VII
and Article VIII of this Agreement; or
(b) such other date as the parties may mutually agree to in
writing.
Code. "Code" shall mean the Internal Revenue Code of 1986, as amended,
and the regulations promulgated thereunder, as the same may be in effect from
time to time.
Confidentiality Agreement. "Confidentiality Agreement" shall mean the
letter agreement between Plexus and SeaMED dated on or about February 8, 1999.
Disclosure Schedule. "Disclosure Schedule" shall mean the Disclosure
Schedule dated the date of this Agreement delivered by SeaMED to Plexus
contemporaneously with the execution and delivery of this Agreement and as the
same may be amended from time to time after the date of this Agreement and prior
to the Closing Date in accordance with the terms of this Agreement.
ERISA. "ERISA" shall mean the Employee Retirement Income Security Act of
1974, as the same may be in effect from time to time.
Employee Stock Purchase Plan. "Employee Stock Purchase Plan" shall mean
the SeaMED 1996 Employee Stock Purchase Plan.
-2-
<PAGE> 9
Exchange Act. "Exchange Act" shall mean the Securities Exchange Act of
1934, as the same may be in effect from time to time.
HSR Act. "HSR Act" shall mean the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, as the same may be in effect from time to time.
Knowledge of Plexus. "Knowledge of Plexus" shall mean, for purposes of
this Agreement, when any fact or matter is stated to be "to the Knowledge of
Plexus" or words of similar import, the actual knowledge of the existence or
nonexistence of such fact or matter, after reasonable inquiry of the executive
officers of Plexus.
Knowledge of SeaMED. "Knowledge of SeaMED" shall mean, for purposes of
this Agreement, when any fact or matter is stated to be " to the Knowledge of
SeaMED" or words of similar import, the actual knowledge of the existence or
nonexistence of such fact or matter, after reasonable inquiry, of W. Robert Berg
and Edgar F. Rampy and, to the extent the representation or warranty is within
the specific area of expertise of another executive officer of SeaMED, such
executive officer of SeaMED.
Law. "Law" shall mean any federal, state, local or other law, rule,
regulation or governmental requirement of any kind, and the rules, regulations
and orders promulgated thereunder by any regulatory agencies.
Merger. "Merger" shall mean the merger of Acquisition with and into
SeaMED pursuant to this Agreement.
Person. "Person" shall mean a natural person, corporation, trust,
partnership, limited liability company, governmental entity, agency or branch or
department thereof, or any other legal entity.
Plexus. "Plexus" shall mean Plexus Corp., a Wisconsin corporation.
Plexus Common Stock. "Plexus Common Stock" shall mean shares of Common
Stock, $.01 par value, of Plexus.
Plexus Companies. "Plexus Companies" shall mean Plexus and all
Subsidiaries of Plexus.
Plexus Material Adverse Effect. "Plexus Material Adverse Effect" shall
mean any event, condition or fact which is materially adverse to the financial
condition, properties, business, results of operations or prospects of the
Plexus Companies taken as a whole, other than (i) events, conditions or facts
arising out of general economic conditions unrelated to the business in which
any of the Plexus Companies are engaged; (ii) events, conditions or facts
arising out of conditions generally affecting the contract manufacturing
industry; (iii) events, conditions or facts arising out of or resulting from the
announcement of the Merger.
-3-
<PAGE> 10
Plexus Stock Value. "Plexus Stock Value" shall mean the closing price of
Plexus Common Stock on the NASDAQ Stock Market on each of the twenty (20)
trading days ending three (3) days prior to the Closing Date.
Proxy Statement. "Proxy Statement" shall mean the proxy
statement/prospectus of SeaMED and Plexus to be filed with the SEC and to be
distributed to the SeaMED Shareholders in connection with the SeaMED Special
Meeting and the approval of the Merger by the SeaMED Shareholders, which shall
also constitute the prospectus of Plexus filed as a part of the Registration
Statement.
Registration Statement. "Registration Statement" shall mean a
registration statement on Form S-4 to be filed under the Securities Act by
Plexus in connection with the Merger for purposes of registering the shares of
Plexus Common Stock to be issued in the Merger pursuant to Article II of this
Agreement.
Rights Agreement. "Rights Agreement" means that certain Rights Agreement
dated January 27, 1998 between SeaMED and Chase Mellon Shareholder Services,
LLC.
SeaMED. "SeaMED" shall mean SeaMED Corporation, a Washington
corporation.
SeaMED Common Stock. "SeaMED Common Stock" shall mean all of the issued
and outstanding shares of common stock, no par value, of SeaMED.
SeaMED Material Adverse Effect. "SeaMED Material Adverse Effect" shall
mean any event, condition or fact which is materially adverse to the financial
condition, properties, business, results of operations or prospects of SeaMED,
other than (i) events, conditions or facts arising out of general economic
conditions unrelated to the business in which SeaMED is engaged; (ii) events,
conditions or facts arising out of conditions generally affecting the medical
device industry; (iii) events, conditions or facts arising out of or resulting
from the announcement of the Merger.
SeaMED Rights. "SeaMED Rights" shall mean the preferred share purchase
rights issued under the Rights Agreement dated January 27, 1998 between SeaMED
and Chase Mellon Shareholder Services, LLC.
SeaMED Special Meeting. "SeaMED Special Meeting" shall mean a special
meeting of the SeaMED Shareholders for the purpose of approving the Merger, this
Agreement and the transactions contemplated by this Agreement and for such other
purposes as may be necessary or desirable.
SeaMED Shareholders. "SeaMED Shareholders" shall mean all Persons owning
shares of SeaMED Common Stock on the relevant date.
SEC. "SEC" shall mean the Securities and Exchange Commission.
-4-
<PAGE> 11
Securities Act. "Securities Act" shall mean the Securities Act of 1933,
as the same may be in effect from time to time.
Subsidiary. "Subsidiary" shall mean any corporation, at least a majority
of the outstanding capital stock of which (of any class or classes, however
designated, having ordinary voting power for the election of at least a majority
of the board of directors of such corporation) shall at the time be owned by the
relevant Person directly or through one or more corporations which are
themselves Subsidiaries.
Voting Agreements. "Voting Agreements" shall mean the agreements of each
of W. Robert Berg, Edgar F. Rampy, and R. Scott Asen in the form of Exhibit D
attached to this Agreement.
WBCA. "WBCA" shall mean the Washington Business Corporation Act, as the
same shall be in effect from time to time.
Year 2000 Compliant. "Year 2000 Compliant" shall mean with respect to a
Person's material hardware and software systems, that such hardware and software
is designed to be used prior to, during, and after the calendar Year 2000 A.D.,
and such hardware and software used during each such time period will accurately
receive, provide and process date/time data from, into and between the twentieth
and twenty-first centuries in all material ways, and will not malfunction, cease
to function, or provide invalid or incorrect results as a result of date/time
data in all material ways, to the extent that other hardware and software, used
in combination with that Person's hardware and software, properly exchanges
date/time data with that Person's hardware and software.
Other Terms. The following terms shall have the meanings specified in
the following noted Sections of this Agreement:
<TABLE>
<CAPTION>
TERM SECTION
- ---- -------
<S> <C>
Break-up Fee 3.9
Cause 3.18
CERCLA 4.24
Effective Time of Merger 2.2
Employee Benefit Plans 4.12
Environmental Claim 4.24
Environmental Hazardous Material 4.24
</TABLE>
-5-
<PAGE> 12
<TABLE>
<S> <C>
Environmental Laws 4.24
Environmental Permits 4.24
Environmental Release 4.24
Exchange Agent 2.8
Exchange Fund 2.8
Exchange Rate 2.6
Existing Contracts 4.9
Existing Liens 4.5
Existing Litigation 4.6
Existing Plans 4.12
Indebtedness 4.9
Indemnified Parties 3.14
Lien 4.5
Other Proposal 3.9
Other Transaction 3.9
Plexus SEC Reports 5.6
Representatives 3.9
Superior Proposal 3.9
Surviving Corporation 2.1
Takeover Proposal 3.9
SeaMED Certificates 2.8
SeaMED Options 2.12
SeaMED Option Plans 2.12
SeaMED SEC Reports 4.7
</TABLE>
-6-
<PAGE> 13
ARTICLE II
THE MERGER
2.1 The Merger. At the Effective Time of Merger and upon and subject
to the terms and conditions of this Agreement, Acquisition will be merged with
and into SeaMED, which shall be the surviving corporation in the Merger (the
"Surviving Corporation") and shall continue to be governed by the Laws of the
State of Washington, and the separate existence of Acquisition shall thereupon
cease. The Merger shall be pursuant to the provisions of, and shall be with the
effects provided in, the WBCA.
2.2 Effective Time of Merger. Subject to the terms and conditions of
this Agreement, on the Closing Date, Acquisition and SeaMED will cause the
Articles of Merger to be executed, delivered and filed as provided in the WBCA.
The Merger shall become effective at the time of the filing of the Articles of
Merger with the Washington Secretary of State or at such later time as Plexus
and SeaMED may agree and as may be set forth in the Articles of Merger. The date
and time on which the Merger shall become effective is referred to in this
Agreement as the "Effective Time of Merger".
2.3 Articles of Incorporation of Surviving Corporation. The Articles
of Incorporation of SeaMED as in effect immediately prior to the Effective Time
of Merger shall be the Articles of Incorporation of the Surviving Corporation
until amended in accordance with Law.
2.4 Bylaws of Surviving Corporation. The Bylaws of SeaMED as in
effect immediately prior to the Effective Time of Merger shall be the Bylaws of
the Surviving Corporation until amended in accordance with Law.
2.5 Directors and Officers of Surviving Corporation. The duly
qualified and acting directors and officers of Acquisition immediately prior to
the Effective Time of Merger shall be the directors and officers of the
Surviving Corporation, to hold office as provided in the Bylaws of the Surviving
Corporation.
2.6 Conversion of SeaMED Common Stock.
(a) Conversion. At the Effective Time of Merger, by virtue
of the Merger and without any action on the part of Acquisition, SeaMED, Plexus
or the SeaMED Shareholders:
(i) Each share of SeaMED Common Stock issued and
outstanding at the Effective Time of Merger, except as provided in subsection
(ii) below, shall be converted into shares of Plexus Common Stock on the terms
and conditions set forth in this Agreement
-7-
<PAGE> 14
subject to the provisions of Section 2.8(e) of this Agreement concerning cash
being paid for fractional shares at the rate of the stated number of shares of
Plexus Common Stock for each share of SeaMED Common Stock, determined as follows
("the Exchange Rate").
(A) If the Plexus Stock Value is equal to or
greater than $30.00, and equal to or less than $37.50, the Exchange Rate
shall be 0.4000 shares of Plexus Common Stock for each share of SeaMED
Common Stock.
(B) In the event the Plexus Stock Value is
equal to or greater than $27.00 but less than $30.00, the Exchange Rate
shall be determined by dividing $12.00 by the Plexus Stock Value.
(C) In the event the Plexus Stock Value is
less than $27.00, the Exchange Rate shall be 0.4444 shares of Plexus
Common Stock for each share of SeaMED Common Stock.
(D) In the event the Plexus Stock Value is
greater than $37.50, the Exchange Rate shall equal $15.00 divided by the
Plexus Stock Value.
In each such case, the Exchange Rate shall be determined to four decimal
places, rounding to the nearest ten thousandth of a share.
(ii) Any shares of SeaMED Common Stock that are owned
by SeaMED at the Effective Time of Merger shall be canceled and retired and
cease to exist and no Plexus Common Stock or other consideration shall be issued
or delivered in exchange therefor. Any shares of SeaMED Common Stock as to which
the holders thereof have perfected dissenter's rights under the WBCA shall be
treated as provided in Section 2.11 of this Agreement.
(b) Adjustment. In the event that, prior to the Effective
Time of Merger, there is a reclassification, stock split or stock dividend with
respect to outstanding Plexus Common Stock or outstanding SeaMED Common Stock,
appropriate and proportionate adjustment, if any, shall be made to the Exchange
Rate.
2.7 Conversion of Acquisition Common Stock. At the Effective Time of
Merger, and without any action on the part of the holders of common stock of
Acquisition, each share of common stock of Acquisition issued and outstanding at
the Effective Time of Merger shall be converted into one (1) share of SeaMED
Common Stock.
2.8 Exchange of SeaMED Certificates.
(a) Exchange Agent. As of the Effective Time of Merger,
Plexus shall deposit, or shall cause to be deposited, with the corporate trust
department of Firstar Bank NA, Milwaukee, Wisconsin, or such other bank or trust
company designated by Plexus and approved by SeaMED, which approval shall not be
unreasonably withheld (the "Exchange Agent"), for the benefit of the SeaMED
Shareholders, for exchange in accordance with this Article II of this
-8-
<PAGE> 15
Agreement through the Exchange Agent, certificates representing the shares of
Plexus Common Stock (such certificates for shares of Plexus Common Stock,
together with any dividends or distributions with respect thereto and together
with any cash for fractional share interests made pursuant to Section 2.8(e) of
this Agreement, being hereinafter referred to as the "Exchange Fund") issuable
pursuant to Section 2.6 of this Agreement in exchange for outstanding shares of
SeaMED Common Stock.
(b) Exchange Procedures.
(i) At or promptly after the Effective Time of
Merger, Plexus shall (i) cause the Exchange Agent to mail to each holder of
record of a certificate or certificates which immediately prior to the Effective
Time of Merger represented outstanding shares of SeaMED Common Stock (the
"SeaMED Certificates"): (A) a letter of transmittal which shall be in such form
and have such provisions as Plexus may reasonably specify; and (B) instructions
to effect the surrender of the SeaMED Certificates in exchange for certificates
representing shares of Plexus Common Stock; and (ii) direct the Exchange Agent
to issue certificates representing that number of whole shares of Plexus Common
Stock to which each holder of uncertificated shares of SeaMED Common Stock (as
reflected on the books and records of SeaMED's transfer agent) is entitled
pursuant to the provisions of this Article II of this Agreement, without any
action on the part of such holders, plus any cash in lieu of any fractional
share interest in accordance with Section 2.8(e) of this Agreement.
(ii) Upon surrender of a SeaMED Certificate for
cancellation to the Exchange Agent together with such letter of transmittal,
duly executed, and with such other documents as the Exchange Agent may
reasonably require, the holder of such SeaMED Certificate shall be entitled to
receive, and Plexus shall cause the Exchange Agent to promptly deliver in
exchange therefor, a certificate representing that number of whole shares of
Plexus Common Stock to which such holder is entitled in respect of such SeaMED
Certificate pursuant to the provisions of this Article II of this Agreement,
plus any cash in lieu of any fractional share interest in accordance with
Section 2.8(e) of this Agreement, and the SeaMED Certificate so surrendered
shall forthwith be canceled; provided, however, that fractional share interests
of any one holder shall be aggregated to maximize the number of whole shares of
Plexus Common Stock to be issued and minimize the fractional interests to be
paid in cash as provided in Section 2.8(e) of this Agreement.
(iii) In the event of a transfer of ownership of
shares of SeaMED Common Stock which is not registered in the transfer records of
SeaMED, a certificate representing the proper number of shares of Plexus Common
Stock, and any cash in lieu of any fractional share interests in accordance with
Section 2.8(e) of this Agreement, shall be delivered to the transferee if the
SeaMED Certificate which represented such shares of SeaMED Common Stock is
presented to the Exchange Agent, accompanied by all documents required to
evidence and effect such transfer and by evidence that any applicable stock
transfer taxes have been paid.
(iv) Until surrendered as contemplated by this
Section 2.8 of this Agreement, each SeaMED Certificate shall be deemed at all
times after the Effective Time of Merger to represent only the right to receive
upon surrender a certificate representing shares of
-9-
<PAGE> 16
Plexus Common Stock and cash in lieu of any fractional share interest as
contemplated by Section 2.8(e) of this Agreement, or in respect of dissenting
shares, the consideration determined pursuant to Section 2.11 of this Agreement.
(c) Distributions with Respect to Unexchanged Shares. No
dividends or other distributions declared or made after the Effective Time of
Merger with respect to Plexus Common Stock with a record date after the
Effective Time of Merger shall be paid to the holder of any unsurrendered SeaMED
Certificate with respect to the shares of Plexus Common Stock represented
thereby, and no cash payment in lieu of a fractional share shall be paid to any
such holder pursuant to Section 2.8(e) of this Agreement, until the holder of
such SeaMED Certificate has surrendered such SeaMED Certificate to the Exchange
Agent. Subject to the effect of any applicable Law, following the surrender of
any such SeaMED Certificate, there shall be paid to the holder of the
certificate representing whole shares of Plexus Common Stock issued in exchange
for the surrendered SeaMED Certificates, without interest: (i) promptly, the
amount of any cash payable with respect to a fractional share interest to which
such holder is entitled pursuant to Section 2.8(e) of this Agreement and the
amount of dividends or other distributions with a record date after the
Effective Time of Merger theretofore paid with respect to such whole shares of
Plexus Common Stock; and (ii) at the appropriate payment date, the amount of
dividends or other distributions with a record date after the Effective Time of
Merger but prior to surrender and a payment date occurring after surrender
payable with respect to such whole shares of Plexus Common Stock.
(d) No Further Rights in SeaMED Common Stock. All shares of
Plexus Common Stock issued upon conversion of the SeaMED Common Stock in
accordance with the terms of this Agreement (and any cash paid pursuant to
Section 2.8(e) of this Agreement) shall be deemed to have been issued (and paid)
in full satisfaction of all rights pertaining to the SeaMED Common Stock.
(e) No Fractional Shares. No fractional shares of Plexus
Common Stock shall be issued in the Merger. All fractional share interests of a
holder of more than one SeaMED Certificate at the Effective Time of Merger shall
be aggregated. If a fractional share interest results after such aggregation,
each holder of a fractional share interest shall be paid an amount in cash equal
to the product obtained by multiplying such fractional share interest by the
Plexus Stock Value. Promptly after the determination of the amount of cash, if
any, to be paid to holders of fractional share interests, the Exchange Agent
shall notify Plexus and Plexus shall direct the Exchange Agent to deliver such
amounts to such holders in accordance with Section 2.8(b) of this Agreement,
subject to and in accordance with the terms of Section 2.8(c) of this Agreement.
(f) Termination of Exchange Fund. Any portion of the
Exchange Fund which remains undistributed to the SeaMED Shareholders after
twelve (12) months after the Effective Time of Merger shall be delivered to
Plexus, upon demand, and any SeaMED Shareholders who have not theretofore
complied with this Article II of this Agreement shall thereafter look only to
Plexus for payment of their claim for shares of Plexus Common Stock, any cash in
lieu of fractional share interests and any dividends or distributions with
respect to Plexus Common Stock.
-10-
<PAGE> 17
(g) No Liability. Neither the Exchange Agent nor any party
to this Agreement shall be liable to any SeaMED Shareholder for any shares of
SeaMED Common Stock or Plexus Common Stock (or dividends or distributions with
respect thereto) or cash delivered to a public official pursuant to any
abandoned property, escheat or similar Law.
(h) Withholding Rights. Subject to the following sentences
of this Section 2.8(h), Plexus shall be entitled to deduct and withhold from the
consideration otherwise payable pursuant to this Agreement to any SeaMED
Shareholder such amounts as Plexus is required to deduct and withhold with
respect to the making of such payment under the Code, or any provision of state,
local or foreign tax Law. If withholding is required for anything other than
back up withholding on cash payments, Plexus will notify SeaMED and provide
SeaMED the right to provide an opinion of legal counsel that no withholding is
covered. To the extent that amounts are withheld by Plexus, such withheld
amounts shall be treated for all purposes of this Agreement as having been paid
to the SeaMED Shareholder in respect of which such deduction and withholding was
made by Plexus.
2.9 Stock Transfer Books. At the Effective Time of Merger, the stock
transfer books of SeaMED shall be closed and there shall be no further
registration of transfers of shares of SeaMED Common Stock thereafter on the
records of SeaMED. From and after the Effective Time of Merger, the holders of
SeaMED Certificates outstanding immediately prior to the Effective Time of
Merger shall cease to have any rights with respect to such shares of SeaMED
Common Stock except as otherwise provided in this Agreement or by Law.
2.10 Reorganization; Pooling. The parties intend that this Agreement
be a plan of reorganization within the meaning of Section 368(a) of the Code and
that the Merger be a tax-free reorganization under Section 368(a) of the Code
and that the Merger qualify for pooling of interests accounting treatment.
2.11 Dissenting Shares. Any shares of SeaMED Common Stock as to which
dissenters' rights are perfected under Chapter 23B.13 of the WBCA shall be
treated in accordance therewith, notwithstanding any other provision of this
Agreement.
2.12 SeaMED Stock Options.
(a) Conversion. At the Effective Time of Merger, each
outstanding option to purchase shares of SeaMED Common Stock (a "SeaMED Option")
under SeaMED's 1988 Stock Option Plan, 1995 Employee Stock Option and Incentive
Plan, and 1997 Employee Nonqualified Stock Option Plan, each as amended (the
"SeaMED Option Plans"), whether vested or unvested, shall be deemed to
constitute an option to acquire, on the same terms and conditions as were
applicable under such SeaMED Option, the same number of shares of Plexus Common
Stock as the holder of such SeaMED Option would have been entitled to receive
pursuant to the Merger had such holder exercised such SeaMED Option in full
immediately prior to the Effective Time of Merger (rounded to the nearest whole
number), at a price per share (rounded down to the nearest whole cent) equal to:
(i) the aggregate exercise price for the shares of SeaMED Common Stock otherwise
purchasable pursuant to such SeaMED Option; divided by (ii) the number of full
shares of Plexus Common Stock deemed purchasable pursuant to such SeaMED Option
in
-11-
<PAGE> 18
accordance with the foregoing; provided, however, that in the case of any SeaMED
Option which is intended to be an "incentive stock option" (as defined in
Section 422 of the Code), the option price, the number of shares purchasable
pursuant to such option and the terms and conditions of exercise of such option
shall be determined in accordance with the foregoing, subject to such
adjustments as are necessary in order to satisfy the requirements of Section
424(a) of the Code. At or prior to the Effective Time of Merger, SeaMED shall
make all necessary arrangements to permit the assumption of the unexercised
SeaMED Options by Plexus pursuant to this Section.
(b) Assumption. Effective at the Effective Time of Merger,
Plexus shall assume each SeaMED Option in accordance with the terms of the
SeaMED Option Plan under which it was issued and all of the terms and conditions
of the stock option agreement by which it is evidenced. At or prior to the
Effective Time of Merger, Plexus shall take all corporate action necessary to
reserve for issuance a sufficient number of shares of Plexus Common Stock for
delivery upon exercise of SeaMED Options assumed by it in accordance with this
Section 2.12 of this Agreement. As soon as practicable after the Effective Time
of Merger, Plexus shall file a registration statement (or a post-effective
amendment to the registration statement) on Form S-8 (or any successor or other
appropriate form) with respect to the Plexus Common Stock subject to such SeaMED
Options, and shall use its best efforts to maintain the effectiveness of such
registration statement (and maintain the current status of the prospectus or
prospectuses relating thereto) for so long as such SeaMED Options remain
outstanding.
2.13 Voting Agreements. Each of W. Robert Berg, Edgar F. Rampy and R.
Scott Asen has delivered a duly executed Voting Agreement, and shall comply with
the terms thereof.
ARTICLE III
OTHER AGREEMENTS
3.1 Proxy Statement and Registration Statement. Plexus and SeaMED
will prepare and file with the SEC the Registration Statement and the Proxy
Statement as soon as reasonably practicable after the date of this Agreement.
Plexus and SeaMED shall use reasonable best efforts to cause the Registration
Statement to be declared effective under the Securities Act as promptly as
practicable after such filing. Plexus and SeaMED shall also take such action as
may be reasonably required to cause the shares of Plexus Common Stock issuable
pursuant to the Merger to be registered or to obtain an exemption from
registration or qualification under applicable state "blue sky" or securities
Laws; provided, however, that Plexus shall not be required to qualify as a
foreign corporation or to file any general consent to service of process under
the Laws of any jurisdiction or to comply with any other requirements deemed by
Plexus to be unduly burdensome. Each party to this Agreement will furnish to the
other parties all information concerning itself as each such other party or its
counsel may reasonably request and which is required or customary for inclusion
in the Proxy Statement and the Registration Statement.
3.2 Approval of SeaMED Shareholders. SeaMED shall, as soon as
reasonably practicable: (i) take all steps necessary duly to call, give notice
of, convene and hold the
-12-
<PAGE> 19
SeaMED Special Meeting; (ii) distribute the Proxy Statement, which shall also
constitute the prospectus of Plexus included in the Registration Statement, to
the SeaMED Shareholders in accordance with applicable federal and state Law and
its Articles of Incorporation and Bylaws; (iii) subject to the provisions of
Section 3.9 of this Agreement, recommend to the SeaMED Shareholders the approval
of this Agreement and the transactions contemplated by this Agreement and such
other matters as may be submitted to the SeaMED Shareholders in connection with
this Agreement; and (iv) cooperate and consult with Plexus with respect to each
of the foregoing matters. The SeaMED Special Meeting shall be held on such date
as is mutually determined by SeaMED and Plexus.
3.3 HSR Act. Each party shall: (a) file or cause to be filed with
the Federal Trade Commission and the Department of Justice any notifications
required to be filed under the HSR Act; and (b) use reasonable best efforts to
make such filings promptly and to respond promptly to any request for additional
information made by either of such agencies.
3.4 Access.
(a) Access to SeaMED and Information. Upon reasonable
notice, SeaMED shall afford to the officers, employees, investment bankers,
agents, accountants, attorneys and representatives of Plexus full access to all
of its books, records, financial information, facilities, key personnel and
other documents and materials except such information as may be subject to
confidentiality agreements with respect to Other Transactions or Other
Proposals; provided that such access shall be upon reasonable notice and during
normal business hours of SeaMED. SeaMED shall provide monthly to Plexus the
monthly management and financial package prepared in the ordinary course of
business by SeaMED for its Board of Directors.
(b) Access to Plexus Companies. Upon reasonable notice,
Plexus shall, and shall cause the other Plexus Companies to, afford to the
officers, employees, investment bankers, agents, accountants, attorneys and
representatives of SeaMED full access to all of its books, records, financial
information, facilities, key personnel and other documents and materials;
provided that such access shall be upon reasonable notice and during normal
business hours of the Plexus Companies.
(c) Confidentiality Agreement. SeaMED and Plexus agree that
the provisions of the Confidentiality Agreement shall remain in full force and
effect; provided that at the Effective Time of Merger, the Confidentiality
Agreement shall be deemed to have terminated without further action by the
parties.
3.5 Disclosure Schedule. Contemporaneously with the execution and
delivery of this Agreement, SeaMED is delivering to Plexus the Disclosure
Schedule. The Disclosure Schedule is deemed to constitute an integral part of
this Agreement and to modify the representations, warranties, covenants or
agreements of SeaMED contained in this Agreement. The Disclosure Schedule may be
updated or amended by SeaMED prior to Closing except to the extent such
modification would disclose a SeaMED Material Adverse Effect.
-13-
<PAGE> 20
3.6 Conditions to Merger. Each party to this Agreement shall use
reasonable best efforts to: (a) to the extent within its control, cause all of
its representations and warranties contained in this Agreement to be true and
correct in all respects on the Closing Date with the same force and effect as if
such representations and warranties had been made on the Closing Date; (b) take
all reasonable actions necessary to comply promptly with all legal requirements
which may be imposed on it with respect to the Merger (including but not limited
to making all filings and requests in connection with approvals of or filings
with any governmental entity as described in Sections 7.7 and 8.7 of this
Agreement and furnishing all information required in connection therewith); (c)
promptly cooperate with and furnish information to the other parties in
connection with any such requirements imposed upon any of them in connection
with the Merger; (d) contest any legal proceedings seeking to restrain, enjoin
or frustrate the Merger, subject, in the case of SeaMED, to the provisions of
Section 3.9(c) of this Agreement concerning Superior Proposals; (e) execute any
additional documents or instruments and take any additional actions reasonably
necessary or appropriate to consummate the transactions contemplated by this
Agreement; and (f) take all reasonable actions necessary to obtain (and
cooperate with the other parties in obtaining) any consent, authorization, order
or approval of, or any exemption by, any governmental entity or other public or
private Person, required to be obtained or made by the parties to this Agreement
in connection with the Merger or the taking of any action contemplated thereby
or by this Agreement.
3.7 Deliveries of Information; Consultation. From time to time prior
to the Effective Time of Merger:
(a) Deliveries by SeaMED. SeaMED shall furnish promptly to
Plexus: (i) a copy of each report, schedule and other document filed by SeaMED
with the SEC pursuant to the requirements of federal securities Laws promptly
after such documents are available; (ii) the monthly financial statements of
SeaMED (as prepared by SeaMED in accordance with its normal accounting
procedures) promptly after such financial statements are available; (iii) a
summary of any action taken by the Board of Directors, or any committee thereof,
of SeaMED; and (iv) all other information concerning the business and properties
of SeaMED as Plexus may reasonably request.
(b) Deliveries by Plexus. Plexus shall promptly furnish to
SeaMED: (i) a copy of each report, schedule and other document filed by Plexus
with the SEC pursuant to the requirements of federal securities Laws promptly
after such documents are available; (ii) the monthly consolidated financial
statements of the Plexus Companies (as prepared by Plexus in accordance with its
normal accounting procedures) promptly after such financial statements are
available; and (iii) all other information concerning the business and
properties of any of the Plexus Companies as SeaMED may reasonably request.
(c) Consultation. SeaMED shall confer and consult with
representatives of the Plexus Companies on a regular basis to report on
operational matters and the general status of ongoing business operations of
SeaMED.
(d) Litigation. Each party to this Agreement shall provide
prompt notice to the other parties of any known litigation, arbitration,
proceeding, governmental investigation,
-14-
<PAGE> 21
citation or action of any kind which may be commenced, threatened or proposed by
any Person concerning the legality, validity or propriety of the transactions
contemplated by this Agreement. If any such litigation is commenced against any
party to this Agreement, the parties shall cooperate in all respects in
connection with such litigation and Plexus shall have the right to assume the
defense thereof at its cost and expense and, if Plexus does assume such defense,
it shall confer regularly with SeaMED and shall not settle any such litigation
without the prior consent of SeaMED, which consent shall not be unreasonably
withheld.
3.8 Affiliates; Accounting and Tax Treatment. Within thirty (30)
days after the date of this Agreement, SeaMED shall identify in a letter to
Plexus, and Plexus shall identify in a letter to SeaMED, all Persons who are
and, to such party's knowledge who will be at the Closing Date, Affiliates of
SeaMED and Plexus, respectively. Each of SeaMED and Plexus shall advise their
respective Affiliates of the resale restrictions imposed by applicable
securities Laws and required to cause the Merger to qualify for
pooling-of-interests accounting treatment, and shall use reasonable best efforts
to obtain from each of their respective Affiliates an executed Affiliate Letter
and shall obtain an executed Affiliate Letter from any Person who becomes an
Affiliate of that Person after the date of this Agreement and on or prior to the
Effective Time of Merger. SeaMED and Plexus will each use its respective
reasonable best efforts to cause the Merger to qualify for pooling-of-interests
accounting treatment and as a reorganization under Section 368(a) of the Code.
3.9 Other Transactions.
3.9.1 Definitions. As used in this Agreement, the following
terms shall have the meanings specified:
(i) "Other Transaction" shall mean any of the
following, other than the Merger as contemplated by this Agreement: (A) a
merger, consolidation, share exchange, exchange of securities, reorganization,
business combination or other similar transaction involving the SeaMED; (B) a
sale, lease, transfer or other disposition of all or a significant portion of
the total assets of SeaMED in a single transaction or series of related
transactions; (C) a sale of, or tender offer or exchange offer for, or
acquisition by any Person or group of beneficial owners of, fifteen percent
(15%) or more of the outstanding shares of capital stock of SeaMED in a single
transaction or series of related transactions; or (D) a public announcement of a
proposal, plan, intention or agreement to do any of the foregoing.
(ii) "Other Proposal" shall mean any request for
information, expression of interest, inquiry, proposal or offer relating in any
manner to an Other Transaction.
3.9.2 Termination of Discussions. SeaMED shall immediately
cease and cause to be terminated all existing discussions and negotiations, if
any, with any parties conducted prior to the date of this Agreement with respect
to any Other Transaction or Takeover Proposal (as defined below), except that
SeaMED may notify such other parties that the discussions and negotiations are
terminated.
-15-
<PAGE> 22
3.9.3 Non Solicitation. From and after the date hereof until
the earlier of the Effective Time of Merger or termination of the Agreement,
subject to the proviso in the next paragraph, SeaMED agrees that neither it nor
any of its officers and directors shall, and that SeaMED shall direct and use
its reasonable best efforts to cause its employees, agents and representatives
(including any investment banker, attorney or accountant retained by it) (such
officers, directors, employees, agents and representatives sometimes
collectively referred to herein as "Representatives") not to, directly or
indirectly, initiate, solicit, encourage or otherwise facilitate any inquiries
or the making of any proposal or offer with respect to an Other Transaction (any
such proposal or offer being herein after referred to as a "Takeover Proposal").
SeaMED further agrees that neither it nor its Representatives shall
directly or indirectly, engage in any negotiations concerning, or provide any
confidential information or data to, or have any discussions with, any Person
relating to a an Other Proposal or Takeover Proposal, whether made before or
after the date of this Agreement, or otherwise facilitate any effort or attempt
to make or implement a Takeover Proposal; PROVIDED, HOWEVER, that nothing
contained in this Agreement shall prevent SeaMED or SeaMED's Board of Directors
from:
(a) complying with Rule 14d-9 or Rule 14e-2 promulgated
under the Exchange Act with regard to a Takeover Proposal;
(b) providing information in response to a request therefor
by a Person if the Person making the inquiry makes the following
representations, and SeaMED has no reason to believe that the representations
are not true, that: (i) the inquiry is made in good faith, (ii) to the knowledge
of such Person, the inquiry has not been solicited by SeaMED or its
Representatives in breach of Section 3.9(c) hereof; (iii) the Person has
reviewed the terms of this Agreement; and (iv) subject to due diligence on the
information received from SeaMED, the Person requesting the information expects
that if it makes an offer to SeaMED it would be a Superior Proposal; provided
that the Person so requesting such information must also (y) execute a
confidentiality agreement on terms substantially equivalent to those contained
in the Confidentiality Agreement and (z) submit with such inquiry a
nonrefundable, good faith deposit in the form of a check payable to SeaMED in
the amount of $50,000, which shall be paid to Plexus in the event that this
Agreement is terminated by Plexus pursuant to Section 9.1(c)(v), (vi), (vii) or
(viii);
(c) engaging in any negotiations or discussions with any
Person who has made an unsolicited bona fide Takeover Proposal; or
(d) withdrawing or modifying the approval or recommendation
by SeaMED's Board of Directors of this Agreement and the Merger in connection
with recommending an unsolicited bona fide written Takeover Proposal to the
stockholders of SeaMED or entering into any agreement with respect to an
unsolicited bona fide written Takeover Proposal;
IF AND ONLY TO THE EXTENT THAT, both (i) in each such case referred to in clause
(b), (c) or (d) above, SeaMED's Board of Directors determines in good faith
after receipt of written advice from outside legal counsel experienced in such
matters that such action is necessary in order for its directors to comply with
their respective fiduciary duties under applicable law; and either (ii) in each
case referred to in clause (c) or (d) above, SeaMED's Board of Directors
-16-
<PAGE> 23
determines in good faith (after consultation with its financial advisor) that
such Takeover Proposal, if accepted, is reasonably likely to be consummated,
taking into account all legal, financial and regulatory aspects of the proposal
and the Person making the proposal and would, if consummated, result in a
transaction superior to the transaction contemplated by this Agreement, taking
into account, among other things, the long term prospects and interests of
SeaMED and its stockholders (any such superior Takeover Proposal being referred
to in this Agreement as a "Superior Proposal"); or (iii) in the case referred to
in clause (b) above, the SeaMED Board of Directors determines (after
consultation with its financial adviser) that there is a reasonable likelihood
that such Person has the financial and other resources to make a Superior
Proposal.
SeaMED agrees that it will take the necessary steps to promptly inform its
Representatives of the obligations undertaken in this Section 3.9.3 and in the
Confidentiality Agreement. SeaMED will promptly notify Plexus if any such
inquiries, proposals or offers are received by, any such information is
requested from, or any such discussions or negotiations are sought to be
initiated or continued with, SeaMED or any of its Representatives relating to a
Takeover Proposal, indicating, in connection with such notice, the name of such
Person and the material terms and conditions of any proposals or offers and
thereafter shall keep Plexus informed, on a current basis, on the status and
terms of any such proposals or offers and the status of any such negotiations or
discussions, except to the extent that the Board of Directors of SeaMED
determines, based upon the written advice of outside legal counsel, that such
action is inconsistent with its fiduciary duties under applicable Law. SeaMED
also will promptly request each Person that has heretofore executed a
confidentiality agreement in connection with its consideration of a Takeover
Proposal to return all confidential information heretofore furnished to such
Person by or on behalf of it or any of its subsidiaries.
3.9.4 Termination. SeaMED may, by notice to Plexus at any time
prior to the Effective Time of Merger, whether before or after the approval by
the SeaMED Shareholders, terminate this Agreement if SeaMED enters into,
executes or agrees to a Superior Proposal following a good faith determination
by the Board of Directors of SeaMED (after compliance by SeaMED with the
provisions of Section 3.9.3 of this Agreement) based upon the written advice of
outside legal counsel, that such action is necessary to fulfill its fiduciary
duties under applicable Law; provided that SeaMED pays Plexus the Break-up Fee
provided in Section 3.9.5 hereof.
3.9.5 Break-up Fee. SeaMED agrees to pay Plexus, (provided
that Plexus is not then in material breach of any representation, warranty,
covenant or agreement contained in this Agreement) within two (2) business days
after the termination of this Agreement (or such later date as may apply in the
case of (ii) below) by wire transfer, the sum of $3.2 Million in immediately
available funds, plus interest on the amounts owed at the prime rate as
announced by Key Bank N.A. in effect from time to time during such period plus
two percent (the "BREAK-UP FEE") in the event that following the date of the
execution of this Agreement, and at or prior to the termination of this
Agreement, any of the following events shall have occurred:
-17-
<PAGE> 24
(i) Plexus shall have terminated this Agreement
pursuant to Section 9.1(c)(v), (vi), (vii) or (viii) hereof; or
(ii) if (A) either (y) SeaMED, any of its
subsidiaries or any of their Representatives shall have taken any actions
pursuant to clause (b) or (c) of the proviso set forth in Section 3.9.3 or (z)
an Other Proposal shall have been made to SeaMED or its stockholders or any
Person shall have publicly announced an intention (whether or not conditional)
to make such an Other Proposal with respect to SeaMED and thereafter this
Agreement is terminated by either Plexus or SeaMED pursuant to Section
9.1(c)(iv) or 9.1(d)(iii), respectively, and (B) SeaMED consummates an agreement
for an Other Transaction within twelve (12) months after termination of this
Agreement, SeaMED shall promptly, but in no event later than the date of such
consummation, pay to Plexus the Break-up Fee.
The right to the payment of the fees set forth in this Section 3.9.5
shall be the exclusive remedy at law or in equity to which Plexus may be
entitled upon termination of this Agreement pursuant to Section 9.1(c)(v), (vi)
or (vii) hereof.
SeaMED acknowledges that the agreements contained in this Section 3.9.5
are an integral part of the transactions contemplated by this Agreement, and
that, without these agreements, Plexus and Acquisition would not enter into this
Agreement. If SeaMED fails to promptly pay the amount due pursuant to this
Section 3.9.5 and, in order to obtain such payment, Plexus commences a suit
which results in a judgment against SeaMED for the fee set forth therein, if
Plexus prevails in such suit, SeaMED shall pay to Plexus its reasonable costs
and expenses (including attorneys' fees) in connection with such suit, together
with interest from the date of termination of this Agreement.
The agreements contained in this Section 3.9.5 of this Agreement are an
integral part of this Agreement and constitute liquidated damages and not a
penalty.
3.10 Letter of SeaMED's Accountants. SeaMED shall use reasonable best
efforts to cause to be delivered a letter of Ernst & Young, LLP, SeaMED's
independent auditors, dated within two (2) business days before the effective
date of the Registration Statement and addressed to SeaMED and Plexus, in form
and substance reasonably satisfactory to Plexus and customary in scope and
substance for cold comfort letters delivered by independent public accountants
in connection with registration statements similar to the Registration
Statement.
3.11 Letter of Plexus's Accountants. Plexus shall use reasonable best
efforts to cause to be delivered a letter of PricewaterhouseCoopers LLP,
Plexus's independent auditors, dated within two (2) business days before the
effective date of the Registration Statement and addressed to Plexus and SeaMED,
in form and substance reasonably satisfactory to SeaMED and customary in scope
and substance for cold comfort letters delivered by independent public
accountants in connection with registration statements similar to the
Registration Statement.
-18-
<PAGE> 25
3.12 Nasdaq Listing. Plexus shall use reasonable best efforts to
provide appropriate notice to cause the shares of Plexus Common Stock to be
issued or reserved for issuance pursuant to this Agreement to qualify for
quotation on the Nasdaq Stock Market.
3.13 Public Announcements. SeaMED, Acquisition and Plexus will
cooperate with and obtain the consent of each other in the development and
distribution of all news releases and other public information disclosures with
respect to this Agreement or any of the transactions contemplated hereby, except
as may be required by Law or the Nasdaq Stock Market, in which case such party
shall not issue any public announcement or statement prior to consultation with
the other parties.
3.14 Indemnification and Insurance.
(a) Indemnification. From and after the Effective Time of
Merger, Plexus shall indemnify and hold harmless, to the fullest extent
permitted under applicable Law (and Plexus shall also advance expenses as
incurred to the extent permitted under applicable Law, provided the Person to
whom expenses are advanced provides an undertaking to repay such advances if it
is ultimately determined that said Person is not entitled to indemnification),
each present and former employee, agent, director or officer of SeaMED and the
heirs, successors and assigns of such Persons (the "Indemnified Parties")
against any amounts incurred by such Indemnified Parties, including without
limitation, losses, claims, damages, liabilities, costs, expenses (including
reasonable attorneys fees incurred in defense or otherwise), judgments and
amounts paid in settlement, in connection with any claim, action, suit,
proceeding or investigation (i) arising out of or relating to the transactions
described in this Agreement or (ii) which arise out of or relate to an
Indemnified Party having served as a committee member, director, officer,
employee or agent of SeaMED, or as a trustee or fiduciary of any Employee
Benefit Plans or otherwise on behalf of SeaMED, whether asserted or commenced
prior to or after the Effective Time of Merger.
(b) Insurance. For at least three (3) years from and after
the Effective Time of Merger, Plexus shall maintain, or shall cause to be
maintained, in effect directors and officers insurance covering those Persons
covered by SeaMED's directors and officers insurance as of the date of this
Agreement. This directors and officers insurance shall be not less in terms of
coverage and amount as the insurance that SeaMED has in effect covering such
officers and directors on the date of this Agreement.
(c) Notice; Procedure. Any Indemnified Party wishing to
claim Indemnification under Section 3.14(a) of this Agreement, upon learning of
any such claim, action, suit, proceeding or investigation, shall promptly notify
Plexus thereof, but the failure to so notify shall not relieve Plexus of any
liability it may have to such Indemnified Party if such failure does not
materially prejudice Plexus. In the event of any such claim, action, suit,
proceeding or investigation (whether arising before or after the Effective Time
of Merger): (i) Plexus shall have the right to assume the defense thereof with
counsel reasonably acceptable to the Indemnified Party and Plexus shall not be
liable to any Indemnified Party for any legal expenses of other counsel
thereafter incurred in connection with the defense thereof, unless the
Indemnified Party shall have been advised by such counsel that there may be one
or more legal
-19-
<PAGE> 26
defenses available to it that are different from or in addition to those
available to the indemnifying party that reasonably may be expected to lead to
conflicts in representation (in which case, if the Indemnified Party notifies
the indemnifying party in writing that it elects separate counsel at the expense
of the indemnifying party, the indemnifying party shall not have the right to
assume the defense of such action on behalf of the Indemnified Party with
respect to such defenses); (ii) the Indemnified Party will cooperate in all
respects as reasonably requested by Plexus in the defense of any such matter,
and in connection therewith shall be entitled to reimbursement by Plexus of
expenses incurred in connection therewith; and (iii) Plexus shall not be liable
for any settlement effected without its prior written consent, which consent
shall not be unreasonably withheld or delayed; provided, however, that Plexus
shall not have any obligation hereunder to any Indemnified Party if a court
shall ultimately determine, and such determination shall have become final and
nonappealable, that the indemnification of such Indemnified Party in the matter
contemplated hereby is prohibited by Law. If such indemnity is not available
with respect to any Indemnified Party, the Plexus and the Indemnified Party
shall contribute to the amount payable in such proportion as is appropriate to
reflect relative faults and benefits.
(d) Indemnified Parties. The provisions of this Section 3.14
are intended to be for the benefit of, and shall be enforceable by, each of the
Indemnified Parties. Nothing in this Section 3.14 shall limit in any way any
other rights to indemnification that any current or former director or officer
of SeaMED may have by contract or otherwise.
(e) Articles of Incorporation; Bylaws. From and after the
Effective Time, SeaMED shall fulfill, assume and honor in all respects the
obligations of SeaMED pursuant to SeaMED's Articles of Incorporation, bylaws,
and any indemnification agreement between SeaMED and any of SeaMED's directors
and officers existing and in force as of the date of this Agreement. SeaMED
agrees that the indemnification obligations set forth in SeaMED's Articles of
Incorporation and bylaws, in each case as of the date of this Agreement, shall
survive the Merger with respect to any matter which is based in whole or in part
on or arises in whole or in part out of the fact that an individual is or was a
director or officer of SeaMED prior to the Effective Time of Merger.
3.15 Agreement of Plexus. From and after the date of this Agreement
and until the Effective Time of Merger, Plexus shall, and shall cause the other
Plexus Companies to, diligently carry on its business only in the regular course
and in substantially the same manner as heretofore, provided that acquisitions
by any of the Plexus Companies of business enterprises engaged in businesses
consistent with the businesses of Plexus Companies shall be permitted under this
Section 3.15 of this Agreement.
3.16 Operation of Subsidiary; Relocation of Facilities. Plexus
acknowledges that it intends to operate SeaMED following the Merger as a
separate profit center to design, engineer and manufacture medical and
commercial products, provided that such operations of SeaMED must be consistent
with Plexus's business plan to maximize the synergies with SeaMED and other
Plexus Companies to expand the manufacturing of medical and commercial products
by SeaMED and Plexus. Plexus acknowledges that it intends to continue to use
SeaMED's name with Plexus's name on a blended basis for at least one (1) year
after the Effective Time of Merger. Plexus acknowledges that it has no current
plans to relocate SeaMED
-20-
<PAGE> 27
operations, and Plexus agrees that after the Effective Time of Merger, it will
use its reasonable business efforts to cause SeaMED to maintain SeaMED's
operations in the Seattle metropolitan area for a period of not less than three
(3) years. The parties acknowledge the timing and location of possible
relocations could be affected by lease terminations and/or opportunities. This
section is not intended to confer upon any person, other than the parties to
this Agreement, any rights or remedies hereunder.
3.17 Employee Benefits. Plexus agrees that SeaMED will, as the
Surviving Corporation, provide benefits for SeaMED employees that are
substantially equivalent to the benefits provided to similarly situated Plexus
employees, with prior service considerations as if such SeaMED employees had
been employed by Plexus for the period for which they were employed by SeaMED;
provided, however, that nothing contained herein shall be considered as
requiring Plexus or SeaMED to continue any specific plan or benefit or as
precluding amendments to any specific plan or benefit; and provided further,
that nothing expressed or implied in this Agreement shall confer upon any
employee, beneficiary, dependent, legal representative or collective bargaining
agent of such employee any right or remedy of any nature or kind whatsoever
under or by reason of this Agreement, including without limitation any right to
employment or to continued employment for any specified period, at any specified
location or under any job category, or any specific benefits or specific
employee benefit plan.
3.18 Severance Benefits. Plexus shall cause the following severance
benefits to be provided to SeaMED employees whose employment is terminated by
Plexus or SeaMED without Cause as a result of the Merger within one year after
the Effective Time of Merger, as follows: except as otherwise provided in
individual employment agreements, employees will receive on termination
severance pay equal to one week base salary for each year of prior service with
SeaMED plus one additional month base salary. For purposes of this Section 3.18,
"Cause" shall mean termination resulting from a good faith determination by
Plexus after reasonable investigation that there has been (x) a failure or
refusal in a material respect to follow the reasonable policies and directives
of Plexus, after being provided with written notice and a reasonable opportunity
to cure; (y) a failure to perform in good faith the duties of his or her
position after being provided with written notice and a reasonable opportunity
to cure; (z) any act involving embezzlement, theft, material dishonesty, or a
conviction of or plea of nolo contendere to a crime involving moral turpitude or
a felony.
3.19 Combined Financial Results. Plexus covenants and agrees that, as
promptly as practicable following the end of Plexus's fiscal year, it will
publicly release the combined financial results of Plexus and the Plexus
Companies (including SeaMED).
3.20 S-3 Registration. Prior to the end of Plexus's fiscal year,
Plexus shall prepare and file with the SEC a registration statement on Form S-3
(or any successor or other appropriate form) for resale of shares of Plexus
Common Stock issued in the Merger to R. Scott Asen, and shall use its best
efforts to have such filing declared effective under the Securities Act as
promptly as practicable thereafter and to continue the effectiveness of such
registration until the first anniversary of the Effective Time of Merger. Plexus
may postpone, for up to sixty (60) days, the filing of such a registration
statement if such registration would give rise to a disclosure obligation that
would not be in the best interest of Plexus's shareholders. If, after the
registration
-21-
<PAGE> 28
statement becomes effective, the continuation of the registration statement
would give rise to a disclosure obligation that would not be in the best
interest of Plexus's shareholders or if Plexus considers it necessary for the
registration statement to be amended, such shareholder shall suspend sales until
Plexus advises him that such disclosure has been made or is no longer required,
or the registration statement has been amended, as the case may be. Plexus shall
promptly notify the shareholder of any event, and use its reasonable best
efforts to minimize any such postponement or suspension.
3.21 Additional Board Actions. SeaMED's Board of Directors shall, on
or before the Closing Date, take all such actions, conditioned upon the
occurrence of the Closing, necessary to redeem all outstanding rights of any
holders of SeaMED Rights and to suspend operation of the Employee Stock Purchase
Plan, and, if necessary, to ensure approval of the Merger under appropriate
sections of WBCA (including without limitation WBCA 23B.19.040).
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF SEAMED
SeaMED hereby represents and warrants to Plexus and Acquisition that,
except as set forth in the relevant section of the Disclosure Schedule:
4.1 Organization; Business.
(a) Organization. SeaMED is a corporation duly and validly
organized and existing under the Laws of its jurisdiction of incorporation.
SeaMED is qualified to do business as a foreign corporation and is in good
standing in all other jurisdictions where the ownership or leasing of property
or the conduct of its business requires qualification as a foreign corporation
by it, except where the failure to so qualify would not have a SeaMED Material
Adverse Effect.
(b) Corporate Power and Authority. SeaMED has: (a) full
corporate power and authority necessary to carry on its business as it is now
conducted and to own, lease and operate its assets and properties; and (b) all
material franchises, permits, licenses, approvals, authorizations and
registrations necessary to carry on its business as it is now conducted and to
own, lease and operate its assets and properties, except where the absence of
any such franchises, permits, licenses, approvals, authorizations or
registrations would not have a SeaMED Material Adverse Effect.
4.2 Capitalization.
(a) Capitalization of SeaMED. The entire authorized capital
stock of SeaMED consists of: (i) 10,000,000 shares of Common Stock, no par
value, of which 5,564,463 shares were issued or outstanding on March 15, 1999;
and (ii) 5,000,000 shares of Preferred Stock, $.01 par value, none of which are
issued or outstanding.
(b) Outstanding Capital Stock; No Subsidiary. All of the
outstanding capital stock of SeaMED is duly authorized, validly issued, fully
paid and nonassessable. At March 8,
-22-
<PAGE> 29
1999, there were options to purchase 520,269 shares outstanding under the SeaMED
Option Plans. Except for such options, rights under the Employee Stock Purchase
Plan and the SeaMED Rights, there are no options, warrants, conversion rights or
other rights to subscribe for or purchase, or other contracts with respect to,
any capital stock of SeaMED. SeaMED has no Subsidiaries.
4.3 Authorization; Enforceability. The execution, delivery and
performance of this Agreement by SeaMED and all of the documents and instruments
required by this Agreement to be executed and delivered by SeaMED are within the
corporate power of SeaMED and: (a) have been duly authorized by the Board of
Directors of SeaMED; and (b) upon the approval of the SeaMED Shareholders, shall
be duly authorized by all necessary corporate action by SeaMED. This Agreement
is, and the other documents and instruments required by this Agreement to be
executed and delivered by SeaMED will be, when executed and delivered by SeaMED,
the valid and binding obligations of SeaMED, enforceable against SeaMED in
accordance with their respective terms, except as the enforcement thereof may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium or
similar Laws generally affecting the rights of creditors and subject to general
equity principles.
4.4 No Violation or Conflict. Subject to the receipt of the
approvals and consents described in Section 8.7 of this Agreement or as set
forth in the Disclosure Schedule, the execution, delivery and performance of
this Agreement by SeaMED do not and will not conflict with or violate: (a) any
Law or the Articles of Incorporation or Bylaws of SeaMED; or (b) any Existing
Contract, except where such conflict or violation would not have a SeaMED
Material Adverse Effect.
4.5 Title to Assets. SeaMED owns good and valid title to the assets
and properties which it owns or purports to own, free and clear of any and all
Liens affecting material assets and properties of SeaMED, except those Liens
identified in the SeaMED SEC Reports or on the Disclosure Schedule as "Existing
Liens" and Liens for taxes not yet due and payable and such other Liens or minor
imperfections of title, if any, which do not materially detract from the value
or interfere with the present use of the affected asset or which individually or
in the aggregate would not have a SeaMED Material Adverse Effect. As used in
this Agreement, the term "Lien" shall mean, with respect to any asset: (a) any
mortgage, pledge, lien, covenant, lease or security interest; and (b) the
interest of a vendor or lessor under any conditional sale agreement, financing
lease or other title retention agreement relating to such asset. SeaMED does not
own, and has never owned, any fee title to real property.
4.6 Litigation. Except for the litigation identified in the SeaMED
SEC Reports or on the Disclosure Schedule as "Existing Litigation": (a) there is
no litigation, arbitration, proceeding, governmental investigation, citation or
action of any kind pending or, to the Knowledge of SeaMED, proposed or
threatened, or resolved since November 1, 1996, against or relating to SeaMED
involving, in each case, (i) an amount in excess of $50,000 or (ii) involving
product liability claims, whether or not insured; (b) there are no actions,
suits or proceedings pending or, to the Knowledge of SeaMED, proposed or
threatened, against SeaMED by any Person which question the legality, validity
or propriety of the transactions contemplated by this Agreement.
-23-
<PAGE> 30
4.7 SeaMED SEC Reports and Books and Records.
(a) Definition. As used in this Agreement, "SeaMED SEC
Reports" shall mean all reports, registration statements, definitive proxy
statements, prospectuses and amendments thereto filed by SeaMED with the SEC
since November 17, 1996 or filed by SeaMED with the SEC after the date of this
Agreement and prior to the Effective Time of Merger.
(b) SeaMED SEC Reports. The SeaMED SEC Reports: (i) complied
or will comply, as the case may be, in all material respects with the then
applicable requirements of the Exchange Act and the Securities Act, as the case
may be, and the rules and regulations of the SEC issued thereunder; and (ii) did
not or will not, as the case may be, contain as of their respective filing dates
any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading.
(c) Financial Statements. The audited financial statements
and unaudited quarterly financial statements of SeaMED included in the SeaMED
SEC Reports have been or will be, as the case may be, prepared in accordance
with generally accepted accounting principles applied on a consistent basis
(except as may be indicated therein or in the notes thereto and except with
respect to unaudited quarterly statements as permitted by Form 10-Q of the SEC)
and fairly present the financial position of SeaMED as of the dates thereof and
the results of their operations and changes in financial position for the
periods then ended, subject, in the case of the unaudited quarterly financial
statements, to normal year-end and audit adjustments and any other adjustments
described therein.
4.8 Absence of Certain Changes. Except as set forth in the
Disclosure Schedule or in the SeaMED SEC Reports, since June 30, 1998 there has
not been any:
(a) SeaMED Material Adverse Effect;
(b) transactions by SeaMED outside the ordinary course of
business, except for the transactions contemplated by this Agreement; or
(c) declaration or payment or setting aside the payment of
any dividend or any distribution in respect of the capital stock of SeaMED
(except for regular quarterly cash dividends on outstanding shares of SeaMED
Common Stock which have been publicly announced by SeaMED) or any direct or
indirect redemption, purchase or other acquisition of any such stock by SeaMED.
4.9 Existing Contracts. The contracts identified on the Disclosure
Schedule by reference to this section or which are exhibits to the SeaMED SEC
Reports ("Existing Contracts") are the only contracts to which SeaMED is a party
or by which SeaMED is bound and which constitute:
-24-
<PAGE> 31
(a) to the Knowledge of SeaMED, a lease of, or agreement to
purchase or sell, any capital assets involving an amount in excess of $500,000;
(b) any union labor contracts;
(c) any management or employment contract which: (i) is in
writing; or (ii) creates other than an at-will employment relationship;
(d) any agreements or notes evidencing any Indebtedness; as
used in this Agreement, the term "Indebtedness" shall mean any liability or
obligation of SeaMED, whether primary or secondary or absolute or contingent:
(i) for borrowed money; or (ii) evidenced by notes, bonds, debentures or similar
instruments; or (iii) secured by Liens on any assets of SeaMED.
(e) an agreement by SeaMED which currently restricts its
ability to compete in any business or in any geographical area;
(f) an agreement restricting the right of SeaMED to use or
disclose any information in its possession, other than confidentiality
agreements relating to (i) potential acquisitions by SeaMED and (ii) engineering
and manufacturing contracts or proposals therefor entered into in the ordinary
course of business;
(g) any written agreement with any Affiliate involving
payments in excess of $100,000, or any indebtedness of any officer or director
of SeaMED to SeaMED (other than advances to employees for employment-related
expenses in the ordinary course of SeaMED's business);
(h) any lease of real estate, or buildings or portions
thereof;
(i) to the Knowledge of SeaMED, any other agreement which:
(i) involves an amount in excess of $500,000, other than engineering and
manufacturing contracts or purchase contracts with suppliers entered into in the
ordinary course of business; or (ii) that is not in the ordinary course of
business; or
(j) guaranties or indemnities (other than engineering and
manufacturing agreements entered into in the ordinary course of business or
other agreements disclosed in the SeaMED SEC Reports).
4.10 Performance of Existing Contracts. SeaMED is not in breach of
any term, covenant or condition of its Existing Contracts, except for breaches
that (i) are subject to a cure period and such cure period has not expired; and
(ii) individually or in the aggregate would not have a SeaMED Material Adverse
Effect. Each of the Existing Contracts is in full force and effect and
constitutes the legal and binding obligation of SeaMED and, to the Knowledge of
SeaMED, constitutes the legal and binding obligation of the other parties
thereto.
-25-
<PAGE> 32
4.11 Insurance Policies. SeaMED currently maintains valid insurance
as disclosed to Plexus. No property damage, personal injury or liability claims
have been made, or are pending, against SeaMED that are not covered by insurance
(except for any deductible amounts imposed by such insurance policies). Within
the past two (2) years, no insurance company has canceled any insurance (of any
type) maintained by SeaMED.
4.12 Employee Benefit Plans.
(a) Definition. As used in this Agreement, the term
"Employee Benefit Plans" shall mean any pension plan, profit sharing plan, bonus
plan, incentive compensation plan, stock ownership plan, stock purchase plan,
stock option plan, stock appreciation plan, employee welfare plan, retirement
plan, deferred compensation plan, fringe benefit program, insurance plan,
severance plan, disability plan, health care plan, sick leave plan, death
benefit plan, defined contribution plan, or any other plan or program to provide
retirement income, fringe benefits or other benefits to former or current
employees of SeaMED.
(b) Existing Plans. Except for the Employee Benefit Plans of
SeaMED identified on the Disclosure Schedule or filed as exhibits to the SeaMED
SEC Reports (the "Existing Plans"), SeaMED does not maintain, nor is it bound
by, any Employee Benefit Plan. All of the Existing Plans are, to the extent
applicable, in compliance in all material respects with ERISA, the Code and all
other applicable Laws. All of the Existing Plans which are intended to meet the
requirements of Section 401(a) or 403(a) of the Code have been determined to be
"qualified" within the meaning of the Code, and, to the Knowledge of SeaMED,
there are no facts which would adversely affect the qualified status of any of
such Existing Plans. Each Existing Plan has been administered in all material
respects in accordance with its terms and is in compliance in all material
respects with all applicable Laws. Any Employee Benefit Plan that is not an
Existing Plan that has been terminated was done so in compliance in all material
respects with all applicable Laws, and, to the Knowledge of SeaMED, there is no
basis for further liability or obligation of SeaMED pursuant to any past
Employee Benefit Plan.
(c) Certain Matters. None of the Existing Plans is subject
to either Title IV of ERISA or Section 412 of the Code.
(d) Prohibited Transactions; Reportable Events. To the
Knowledge of SeaMED, no prohibited transaction within the meaning of Section
4975 of the Code or Section 406 of ERISA or reportable event as described in
Section 4043 of ERISA has occurred with respect to any of the Existing Plans.
(e) Multiemployer Plans. SeaMED is not contributing to, nor
has SeaMED contributed to since September 2, 1974, any "multiemployer plan" as
defined in Section 4001(a)(3) of ERISA.
(f) Claims. There are no pending, or to the Knowledge of
SeaMED, threatened claims with respect to any of the Existing Plans, other than
claims for benefits arising in the ordinary course of business.
-26-
<PAGE> 33
(g) Welfare Benefits. Except as set forth on the Disclosure
Schedule, neither SeaMED nor any Existing Plan provides or has any obligation to
provide (or contribute to the cost of) post-retirement (or post-termination of
service) welfare benefits with respect to current or former employees of SeaMED,
including without limitation post-retirement medical, dental, life insurance,
severance or any similar benefit, whether provided on an insured or self-insured
basis.
(h) Welfare Plans. Except as otherwise provided in this
Agreement, each Existing Plan that is an "employee welfare benefit plan" as
defined in ERISA may be amended or terminated at any time after the Effective
Time of Merger without liability to SeaMED.
(i) COBRA. With respect to each Existing Plan, to the
Knowledge of SeaMED, SeaMED has complied in all material respects with the
applicable health care continuation and notice provisions of the Consolidation
Omnibus Budget Reconciliation Act of 1985 and the proposed regulations
thereunder, and the applicable requirements of the Family and Medical Leave Act
of 1993 and the regulations thereunder.
(j) The Merger. The Merger and the consummation of the
transactions contemplated by this Agreement will not entitle any current or
former employee of SeaMED to severance benefits or any other payment, except as
set forth in the Disclosure Schedule, or accelerate the time of paying or
vesting, or increase the amount of compensation due any such employee.
(k) Copies. Correct and complete copies of all Existing
Plans, together with recent summary plan descriptions, have been delivered by
SeaMED to Plexus.
4.13 No Violation of Law. To the Knowledge of SeaMED, neither SeaMED
nor any of the assets of SeaMED violate or conflict in any material respect with
any Law. Without limitation, to the Knowledge of SeaMED, SeaMED is in compliance
with all applicable rules, requirements and permits of the federal Food and Drug
Administration, and other federal agencies with respect to the design and
manufacture of medical devices and products, except such as would not have a
SeaMED Material Adverse Effect. All materials permits or other governmental
authorizations maintained or required to be maintained for the conduct of
SeaMED's business are set forth in the Disclosure Schedule.
4.14 Brokers. Except for fees to US Bancorp Piper Jaffray Inc.,
SeaMED has not incurred any brokers', finders' or any similar fee in connection
with the transactions contemplated by this Agreement.
-27-
<PAGE> 34
4.15 Taxes.
(a) Tax Returns. SeaMED has timely and properly filed all
federal, state, local and foreign tax returns (including but not limited to
income, business, franchise, sales, payroll, employee withholding and social
security and unemployment) which were required to be filed. SeaMED has paid or
made adequate provision, in reserves reflected in its financial statements
included in the SeaMED SEC Reports in accordance with generally accepted
accounting principles, for the payment of all taxes (including interest and
penalties) and withholding amounts owed by it or assessable against it. No
material tax deficiencies have been proposed or assessed against SeaMED. Except
as disclosed in the Disclosure Schedule, there have been no tax audits of SeaMED
and there have been no adjustments in respect of the income of or taxes payable
by SeaMED or in respect of the withholding effected by SeaMED.
(b) Extensions. SeaMED has not consented to any extension of
the statute of limitation with respect to any open tax returns.
(c) Tax Liens. There are no tax Liens upon any property or
assets of SeaMED except for Liens for current taxes not yet due and payable.
(d) Delivery of Tax Returns. SeaMED has made available, and
will deliver upon request, to Plexus correct and complete copies of all tax
returns and reports of SeaMED filed for all periods not barred by the applicable
statute of limitations. No examination or audit of any tax return or report for
any period not barred by the applicable statute of limitations has occurred, no
such examination is in progress and, to the Knowledge of SeaMED, no such
examination or audit is planned.
(e) Employment Taxes. SeaMED has properly withheld and
timely paid all withholding and employment taxes which it was required to
withhold and pay relating to salaries, compensation and other amounts heretofore
paid to its employees or other Persons. All Forms W-2 and 1099 required to be
filed with respect thereto have been timely and properly filed.
(f) Tax Sharing Agreements. SeaMED is not a party to any
agreement relating to allocating or sharing any taxes.
(g) Excess Parachute Payments. SeaMED is not a party to any
contract that could result, on account of the Merger, separately or in the
aggregate, in the payment of any "excess parachute payments" within the meaning
of Section 280G of the Code.
(h) Liabilities of Other Persons. SeaMED has no liability
for taxes of any kind of any Person other than SeaMED under any contract or
under Treasury Regulations Section 1.1502-6 (or any similar provision of Law) as
a transferee or successor or otherwise.
4.16 Governmental Approvals. No permission, approval, determination,
consent or waiver by, or any declaration, filing or registration with, any
governmental or regulatory authority is required in connection with the
execution, delivery and performance of this
-28-
<PAGE> 35
Agreement by SeaMED and the consummation of the Merger, except for: (a) the
approvals described in Section 8.7 of this Agreement; and (b) the filing of the
Articles of Merger as described in this Agreement.
4.17 No Pending Other Transactions. Except for this Agreement, SeaMED
is not a party to or bound by any agreement, undertaking or commitment with
respect to an Other Transaction.
4.18 Labor Matters.
(a) Employee Claims. Except as set forth in the Disclosure
Schedule, there are no pending and unresolved material claims by any Person
against SeaMED arising out of any statute, ordinance or regulation relating to
discrimination against employees or employee practices or occupational or safety
and health standards. There is no pending or, to the Knowledge of SeaMED,
threatened, labor dispute, strike or work stoppage.
(b) NLRB Matters. There is not now pending or, to the
Knowledge of SeaMED, threatened, any material charge or complaint against SeaMED
by or before the National Labor Relations Board or any representative thereof,
or any comparable state agency or authority. To the Knowledge of SeaMED, no
union organizing activities are in process or contemplated and no petitions have
been filed for union organization or representation of employees of SeaMED not
presently organized, and to the Knowledge of SeaMED, SeaMED has not committed
any unfair labor practices which have not heretofore been corrected and fully
remedied.
4.19 Disclosure. No statement of fact by SeaMED contained in this
Agreement or in the Disclosure Schedule contains or will contain any untrue
statement of a material fact or omits or will omit to state a material fact
necessary in order to make the statements herein or therein contained, in the
light of the circumstances under which they were made, not misleading as of the
date to which it speaks.
4.20 Information Supplied. None of the information supplied or to be
supplied by SeaMED for inclusion or incorporation by reference in: (a) the
Registration Statement will, at the time the Registration Statement is filed
with the SEC and at the time it becomes effective under the Securities Act,
contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein
not misleading; and (b) the Proxy Statement will, at the date mailed to the
SeaMED Shareholders and at the time of the SeaMED Special Meeting, contain any
untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary in order to make the statements therein, in
light of the circumstances under which they are made, not misleading. The Proxy
Statement will comply as to form in all material respects with the provisions of
the Exchange Act and the rules and regulations thereunder.
4.21 Vote Required. The affirmative vote of the holders of two-thirds
of the outstanding shares of SeaMED Common Stock is the only vote of the holders
of any class or
-29-
<PAGE> 36
series of capital stock or other securities of SeaMED entitled to vote necessary
to approve the Merger, this Agreement and the transactions contemplated by this
Agreement.
4.22 Accounting Matters. Neither SeaMED nor, to the Knowledge of
SeaMED, any of the Affiliates of SeaMED, has taken or agreed to take or will
take any action that would prevent the Merger being accounted for as a pooling
of interests for financial accounting purposes in accordance with generally
accepted accounting principles and the rules, regulations and interpretations of
the SEC.
4.23 Opinion of Financial Advisor. SeaMED has received a written
opinion of US Bancorp Piper Jaffray Inc., dated the date of this Agreement, to
the effect that the consideration to be received by the SeaMED Shareholders in
the Merger is fair to such SeaMED Shareholders from a financial point of view,
and SeaMED will promptly deliver a copy of such opinion to Plexus.
4.24 Environmental Protection.
(a) Definitions. As used in this Agreement:
(i) "Environmental Claim" shall mean any and all
administrative, regulatory or judicial actions, suits, demands, demand letters,
directives, claims, Liens, investigations, proceedings or notices of
noncompliance or violation (written or oral) by any Person alleging potential
liability (including, without limitation, potential liability for enforcement,
investigatory costs, cleanup costs, governmental response costs, removal costs,
remedial costs, natural resources damages, property damages, personal injuries,
or penalties) arising out of, based on or resulting from: (A) the presence, or
release into the environment, of any Environmental Hazardous Materials at any
location, whether or not owned by SeaMED; or (B) circumstances forming the basis
of any violation or alleged violation, of any Environmental Law; or (C) any and
all claims by any Person seeking damages, contribution, indemnification, cost,
recovery, compensation or injunctive relief resulting from the presence or
Environmental Release of any Environmental Hazardous Materials.
(ii) "Environmental Hazardous Materials" shall mean:
(A) any petroleum or petroleum products, radioactive materials, asbestos in any
form that is or could become friable, urea formaldehyde foam insulation, and
transformers or other equipment that contain dielectric fluid containing levels
of polychlorinated biphenyls (PCBs) and radon gas, in such forms and at such
concentrations as are regulated by an Environmental Law; and (B) any chemicals,
materials or substances which are now defined as or included in the definition
of "hazardous substances," "hazardous wastes," "hazardous materials," "extremely
hazardous wastes," "restricted hazardous wastes," "toxic substances," "toxic
pollutants," or words of similar import, in such forms and at such
concentrations as are regulated by any Environmental Law; and (C) any other
chemical, material, substance or waste, in such forms and at such concentrations
that exposure to them is now prohibited, limited or regulated by any
governmental authority under Environmental Laws.
-30-
<PAGE> 37
(iii) "Environmental Laws" shall mean all federal,
state or local statute, Law, rules, ordinances, codes, rules of common law and
regulations governing pollution or protecting human health or the environment
(including, without limitation, ambient air, surface water, ground water, land
surface or subsurface strata), as may include, without limitation, Laws and
regulations governing Environmental Releases or threatened Environmental
Releases of Environmental Hazardous Materials, and as may include any Laws or
regulations otherwise governing the manufacture, processing, distribution, use,
treatment, storage, disposal, transport or handling of Environmental Hazardous
Materials.
(iv) "Environmental Release" shall mean any release,
spill, emission, leaking, injection, deposit, disposal, discharge, dispersal,
leaching or migration into the atmosphere, soil, surface water or groundwater
which would form the basis of liability under an Environmental Claim.
(b) Compliance With Laws. Except as set forth in the
Disclosure Schedule or in the SeaMED SEC Reports, SeaMED: (i) is in compliance
in all material respects with all applicable Environmental Laws and laws
regulating the storage and disposal of biomedical waste; and (ii) has not
received within the past ten (10) years any written communication from a
governmental authority that alleges that it is not in compliance with applicable
Environmental Laws and laws regulating the storage and disposal of biomedical
waste.
(c) Environmental Permits. Except as set forth in the
Disclosure Schedule or in the SeaMED SEC Reports, SeaMED has obtained all
material environmental, health and safety permits and governmental
authorizations necessary for its operations under Environmental Laws
(collectively, the "Environmental Permits"), and all such Environmental Permits
are in good standing and it is in material compliance with all terms and
conditions of the Environmental Permits.
(d) Environmental Claims. Except as set forth in the
Disclosure Schedule or in the SeaMED SEC Reports, there is no Environmental
Claim pending or, to the Knowledge of SeaMED, threatened, against SeaMED or
against any Person whose liability for any Environmental Claim SeaMED has or may
have retained or assumed either contractually or, to the Knowledge of SeaMED, by
operation of Law, or against any real or personal property or operations which
SeaMED owns, leases or manages.
-31-
<PAGE> 38
(e) Environmental Hazardous Materials. Except as set forth
in the Disclosure Schedule or in the SeaMED SEC Reports, to the Knowledge of
SeaMED, there have been no Environmental Releases of any Environmental Hazardous
Material that were in violation of any Environmental Laws, or that were required
to be reported under Environmental Laws, by SeaMED or by any Person on real
property owned, leased or operated by SeaMED during the time while SeaMED owned,
leased or operated such real property.
(f) Owned Properties. Except as set forth in the Disclosure
Schedule or in the SeaMED SEC Reports, to the Knowledge of SeaMED, no real
property at any time owned, operated, used or controlled by SeaMED is currently
listed on the National Priorities List promulgated under the Comprehensive
Environmental Response, Compensation and Liability Act of 1980, as amended
("CERCLA"), or on any comparable state list, and SeaMED has not received any
written notice from any Person of potential or actual liability or a request for
information from any Person under or relating to CERCLA or any comparable state
or local Environmental Law.
(g) Off-Site Properties. To the Knowledge of SeaMED, no
off-site location at which SeaMED has disposed or arranged for the disposal of
any waste is listed on the National Priorities List or on any comparable state
list and SeaMED has not received within the past ten (10) years any written
notice from any Person with respect to any off-site location, of potential or
actual liability or a written request for information from any Person under or
relating to CERCLA or any comparable state or local Environmental Law.
4.25 Year 2000 Compliance. All of the material internal computer
hardware and software systems of SeaMED as of the date of this Agreement
(including, without limitation, those related to their facilities, equipment
manufacturing processes, quality control activities, accounting and bookkeeping
records and record keeping activities, and excluding in all cases any and all
external hardware and software systems, including, without limitation, software
developed by SeaMED or third parties for use in products produced by SeaMED for
its customers) are presently or will be prior to December 31, 1999 Year 2000
Compliant.
-32-
<PAGE> 39
4.26 Customers. Since June 30, 1998, SeaMED has not experienced any
loss of customer relations with any customers which, individually or in the
aggregate, represented more than five percent (5%) of SeaMED's net sales in its
fiscal year ended June 30, 1998, nor has SeaMED received any notice from any
such customers of their intent to terminate their business with SeaMED.
4.27 Software Licenses. SeaMED is not a party to any software license
agreement material to its business other than those disclosed on the Disclosure
Schedule or that are commercially available under a "shrink wrap" license upon
payment of an applicable fee.
4.28 Additional Board Approvals. SeaMED's Board of Directors has
approved the Merger as a "Permitted Offer" under SeaMED's Rights Plan and for
purposes of WBCA 23B.19.040.
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF
PLEXUS AND ACQUISITION
Plexus and Acquisition hereby represent and warrant to SeaMED that:
5.1 Organization.
(a) Organization. Each of the Plexus Companies and
Acquisition is a corporation duly and validly organized and existing under the
Laws of its respective jurisdiction of incorporation and is qualified to do
business as a foreign corporation and is in good standing in all other
jurisdictions where the ownership or leasing of property or the conduct of its
business requires qualification as a foreign corporation, except where the
failure to so qualify would not have a Plexus Material Adverse Effect.
(b) Corporate Power and Authority. Each of the Plexus
Companies and Acquisition has: (a) full corporate power and authority necessary
to carry on its business as it is now conducted and to own, lease and operate
its assets and properties; and (b) all material franchises, permits, licenses,
approvals, authorizations and registrations necessary to carry on its business
as it is now conducted and to own, lease and operate its assets and properties,
except where the absence of any such franchises, permits, licenses, approvals,
authorizations or registrations would not have a Plexus Material Adverse Effect.
5.2 Capitalization.
(a) Capitalization of Plexus. The entire authorized capital
stock of Plexus consists of: (i) 60,000,000 shares of Common Stock, $.01 par
value, of which 15,147,572 shares were issued or outstanding on March 4, 1999;
and (ii) 5,000,000 shares of Preferred Stock, $.01 par value, none of which are
issued or outstanding. The Plexus Company has issued, in tandem with each share
of Plexus Common Stock, Preferred Stock Purchase Rights, as described in
Plexus's Current Report on Form 8-K dated as of August 13, 1998.
-33-
<PAGE> 40
(b) Outstanding Capital Stock. All of the outstanding shares
of Plexus Common Stock are, and the shares of Plexus Common Stock to be issued
pursuant to this Agreement will be when issued: (i) duly authorized, validly
issued and fully paid; and (ii) nonassessable, except as provided in Section
180.0622(2)(b) of the Wisconsin Business Corporation Law, as judicially
interpreted, which provides that shareholders of Wisconsin corporations may be
assessable for certain unpaid claims for services by employees.
5.3 Authorization; Enforceability. The execution, delivery and
performance of this Agreement by Plexus and Acquisition and all of the documents
and instruments required by this Agreement to be executed and delivered by
Plexus and Acquisition are within the corporate power of Plexus and Acquisition
and: (a) have been duly authorized by the Boards of Directors of Plexus and
Acquisition; and (b) have been duly authorized by all necessary corporate action
by Plexus and Acquisition. This Agreement is, and the other documents and
instruments required by this Agreement to be executed and delivered by Plexus
and Acquisition will be, when executed and delivered by Plexus and Acquisition,
the valid and binding obligations of Plexus and Acquisition, enforceable against
Plexus and Acquisition in accordance with their respective terms, except as the
enforcement thereof may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium or similar Laws generally affecting the rights of
creditors and subject to general equity principles.
5.4 No Violation or Conflict. Subject to the receipt of the
approvals and consents described in Section 7.7 of this Agreement, the
execution, delivery and performance of this Agreement by Plexus and Acquisition
do not and will not conflict with or violate: (a) any Law or the Articles of
Incorporation or Bylaws of any of the Plexus Companies or the Articles of
Incorporation or Bylaws of Acquisition; or (b) any material contract or
agreement to which any of the Plexus Companies or Acquisition is a party or by
which any of them is bound, except where such conflict or violation would not
have a Plexus Material Adverse Effect.
5.5 Litigation. (a) Except as disclosed in the Plexus SEC Reports
filed prior to the date of this Agreement, there is no litigation, arbitration,
proceeding, governmental investigation, citation or action of any kind pending
or, to the Knowledge of Plexus, proposed or threatened against or relating to
any of the Plexus Companies which, if adversely determined against any of the
Plexus Companies, individually or in the aggregate, would or would be reasonably
likely to result in a Plexus Material Adverse Effect. (b) There are no actions,
suits or proceedings pending or, to the Knowledge of Plexus, proposed or
threatened, against any of the Plexus Companies by any Person which question the
legality, validity or propriety of the transactions contemplated by this
Agreement.
5.6 Plexus SEC Reports.
(a) Definition. As used in this Agreement, "Plexus SEC
Reports" shall mean all reports, registration statements, definitive proxy
statements, prospectuses and amendments thereto filed by Plexus with the SEC
since October 1, 1995 or filed by Plexus with the SEC after the date of this
Agreement and prior to the Effective Time of Merger.
-34-
<PAGE> 41
(b) Plexus SEC Reports. The Plexus SEC Reports: (i) complied
or will comply, as the case may be, in all material respects with the then
applicable requirements of the Exchange Act and the Securities Act, as the case
may be, and the rules and regulations of the SEC issued thereunder; and (ii) did
not or will not, as the case may be, contain as of their respective filing dates
any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading.
(c) Financial Statements. The audited consolidated financial
statements and unaudited consolidated interim financial statements of Plexus
included in the Plexus SEC Reports have been or will be, as the case may be,
prepared in accordance with generally accepted accounting principles applied on
a consistent basis (except as may be indicated therein or in the notes thereto
and except with respect to unaudited statements as permitted by Form 10-Q of the
SEC) and fairly present the consolidated financial position of the Plexus
Companies as of the dates thereof and the consolidated results of their
operations and changes in financial position for the periods then ended,
subject, in the case of the unaudited consolidated interim financial statements,
to normal year-end and audit adjustments and any other adjustments described
therein.
5.7 Brokers. Except for fees to Needham & Company, Inc., neither
Plexus nor Acquisition has incurred any brokers', finders' or any similar fee in
connection with the transactions contemplated by this Agreement.
5.8 Governmental Approvals. No permission, approval, determination,
consent or waiver by, or any declaration, filing or registration with, any
governmental or regulatory authority is required in connection with the
execution, delivery and performance of this Agreement by Plexus and Acquisition
and the consummation of the Merger, except for: (a) the approvals described in
Section 7.7 of this Agreement; and (b) the filing of the Articles of Merger as
described in this Agreement.
5.9 Disclosure. No statement of fact by Plexus or Acquisition
contained in this Agreement contains or will contain any untrue statement of a
material fact or omits or will omit to state a material fact necessary in order
to make the statements herein, in the light of the circumstances under which
they were made, not misleading as of the date to which it speaks.
5.10 Information Supplied. None of the information supplied or to be
supplied by Plexus for inclusion or incorporation by reference in (a) the
Registration Statement will, at the time the Registration Statement is filed
with the SEC and at the time it becomes effective under the Securities Act,
contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein
not misleading and (b) the Proxy Statement will, at the date mailed to the
SeaMED Shareholders and at the time of the SeaMED Special Meeting, contain any
untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary in order to make the statements therein, in
light of the circumstances under which they were made, not misleading. The
Registration Statement, including the Proxy Statement insofar as it constitutes
the prospectus of Plexus, will
-35-
<PAGE> 42
comply as to form in all material respects with the provisions of the Securities
Act and the rules and regulations thereunder.
5.11 Accounting Matters. Neither Plexus nor, to the Knowledge of
Plexus, any of the Affiliates of Plexus, has taken or agreed to take or will
take any action that would prevent the Merger being accounted for as a pooling
of interests for financial accounting purposes in accordance with generally
accepted accounting principles and the rules, regulations and interpretations of
the SEC.
5.12 Absence of Certain Changes. Since September 30, 1998, there has
not been (i) any Plexus Material Adverse Effect or, (ii) prior to the execution
hereof, transactions by Plexus or Plexus Companies outside the ordinary course
of business, except for the transactions contemplated by this Agreement or as
disclosed in Plexus SEC Reports.
5.13 No Violation of Law. To the Knowledge of Plexus, neither Plexus,
Plexus Companies nor any of their respective assets violate or conflict in any
material respect with any Law. Without limitation, to the Knowledge of Plexus,
Plexus and Plexus Companies whose business activities are subject to the rules,
requirements and permits of the Federal Food and Drug Administration, and other
federal agencies with respect to the design and manufacture of medical devices
and products, are in compliance with all such applicable rules, requirements and
permits, except such as would not have a Plexus Material Adverse Effect.
5.14 Year 2000 Compliance. All of the material internal computer
hardware and software systems of Plexus and Plexus Companies (including, without
limitation, those related to their facilities, equipment manufacturing
processes, quality control activities, accounting and bookkeeping records and
record keeping activities, and excluding in all cases any and all external
hardware and software systems, including, without limitation, software developed
by Plexus or third parties for use in products produced by Plexus for its
customers) are presently or will be prior to December 31, 1999 Year 2000
Compliant.
5.15 Customers. Since September 30, 1998, Plexus has not experienced
any loss of customer relations with any customers which, individually or in the
aggregate, represented more than five percent (5%) of SeaMED's net sales in its
fiscal year ended September 30, 1998, nor has Plexus received any notice from
any such customers of their intent to terminate their business with Plexus.
-36-
<PAGE> 43
ARTICLE VI
CONDUCT OF BUSINESS BY SEAMED
PENDING THE MERGER
Except with the written consent of Plexus (which consent may not be
unreasonably withheld for all matters in this Article VI of this Agreement
except for Sections 6.10 and 6.11), from and after the date of this Agreement
and until the Effective Time of Merger, SeaMED shall:
6.1 Carry on in Regular Course. Diligently carry on its business in
the regular course and substantially in the same manner as heretofore and shall
not make or institute any unusual or novel methods of purchase, sale, lease,
management, accounting or operation.
6.2 Use of Assets. Use, operate, maintain and repair all of its
assets and properties in a normal business manner.
6.3 No Default. Not do any act or omit to do any act, or permit any
act or omission to act, which will cause a material breach of any of the
Existing Contracts.
6.4 Employment Matters. Not: (a) except as described in the
Disclosure Schedule or as consistent with its normal business practices
consistent with past practice, grant any increase in the rate of pay of any of
its employees, directors or officers; (b) except as otherwise provided in this
Agreement, institute or amend any Employee Benefit Plan; or (c) except as
described in the Disclosure Schedule, enter into or modify any written
employment arrangement with any Person.
6.5 Indebtedness. Not create, incur or assume any Indebtedness,
except for Indebtedness incurred in the ordinary course of business by SeaMED
consistent with past practice.
6.6 Preservation of Relationships. Use reasonable best efforts to
preserve its business organization intact, to retain the services of its present
officers and key employees and to preserve the goodwill of suppliers, customers,
creditors and others having business relationships with it.
6.7 Compliance with Laws. Comply in all material respects with all
applicable Laws.
6.8 Taxes. Timely and properly file all federal, state, local and
foreign tax returns which are required to be filed, and shall pay or make
provision for the payment of all taxes owed by it.
6.9 Amendments. Not amend its Articles of Incorporation or Bylaws.
-37-
<PAGE> 44
6.10 Dividends; Redemptions; Issuance of Stock. Not:
(a) (i) issue any additional shares of stock of any class
(including any shares of preferred stock) except for issuances of shares of
SeaMED Common Stock upon the exercise of options outstanding on the date of this
Agreement under the SeaMED Option Plans and purchases of SeaMED Common Stock
under SeaMED's Employee Stock Purchase Plan, or (ii) grant any warrants, options
or other rights to subscribe for or acquire any additional shares of stock of
any class, except for options for up to 16,000 shares per quarter in the
ordinary course of business consistent with prior practice, unless, after
consultation with Plexus and their respective accounting firms, there is a
reasonable likelihood that such option grants may adversely affect the ability
of Plexus to account for the Merger using the pooling of interest accounting
method.
(b) declare or pay any dividend or make any capital or
surplus distributions of any nature; or
(c) directly or indirectly redeem purchase or otherwise
acquire, recapitalize or reclassify any of its capital stock or liquidate in
whole or in part.
6.11 No Dispositions or Acquisitions. Not: (a) sell, lease, license,
encumber or otherwise dispose of, or agree to sell, lease, license, encumber or
otherwise dispose of, any of its assets, except in the ordinary course of
business consistent with past practice; or (b) acquire, or publicly propose to
acquire or agree to acquire, by merger or consolidation with, or by purchase or
otherwise, an equity interest in, or all or any portion of the assets of, any
Person.
ARTICLE VII
CONDITIONS PRECEDENT TO THE OBLIGATIONS
OF PLEXUS AND ACQUISITION
Each and every obligation of Plexus and Acquisition to be performed on
the Closing Date shall be subject to the satisfaction prior to or at the Closing
of the following express conditions precedent:
7.1 Compliance with Agreement. SeaMED shall have performed and
complied: (a) in all respects with all of its obligations under Sections 6.10
and 6.11 this Agreement which are to be performed or complied with by it prior
to or on the Closing Date; and (b) in all respects with all of its other
obligations under this Agreement which are to be performed or complied with by
it prior to or on the Closing Date, except where the failure to perform or
comply, individually or in the aggregate, would not or would not be reasonably
likely to result in a SeaMED Material Adverse Effect.
7.2 No Litigation. No suit, action or other proceeding shall be
pending before any court in which the consummation of the transactions
contemplated by this Agreement is restrained or enjoined.
-38-
<PAGE> 45
7.3 Representations and Warranties of SeaMED The representations and
warranties made by SeaMED in this Agreement, as modified by the Disclosure
Schedule as of the date of this Agreement, shall be true and correct in all
respects when made and as of the Closing Date with the same force and effect as
though said representations and warranties had been made on the Closing Date,
except where the effect of any breaches of the representations and warranties of
SeaMED made in this Agreement, individually or in the aggregate, would not or
would not be reasonably likely to result in a SeaMED Material Adverse Effect.
7.4 No SeaMED Material Adverse Effect. During the period from the
date of this Agreement to the Closing Date there shall not have occurred, and be
continuing on the Closing Date, any SeaMED Material Adverse Effect.
7.5 Approval of SeaMED Shareholders; Articles of Merger. This
Agreement, the Merger and the transactions contemplated by this Agreement shall
have received the requisite approval and authorization of the SeaMED
Shareholders. The Articles of Merger shall have been executed and delivered by
SeaMED.
7.6 Closing Certificate. SeaMED shall have delivered to Plexus a
certificate signed on behalf of SeaMED by the Chief Executive Officer and Chief
Financial Officer of SeaMED, dated the Closing Date, to the effect that, to the
best of such officers' knowledge, the conditions set forth in Sections 7.1 and
7.3 of this Agreement have been satisfied.
7.7 Governmental Approvals.
(a) Registration Statement. The Registration Statement shall
have been declared effective under the Securities Act and shall not be the
subject of any stop order or proceedings to effect a stop order. The Plexus
Common Stock issuable pursuant to the Merger shall have been registered or shall
be exempt from registration or qualification under applicable state "blue sky"
or securities Laws.
(b) HSR Act. All necessary requirements of the HSR Act shall
have been complied with and any "waiting periods" applicable to the Merger and
to the transactions described in this Agreement which are imposed by the HSR Act
shall have expired prior to the Closing Date or shall have been terminated by
the appropriate agency.
7.8 Accountant Letter. Plexus shall have received a copy of a letter
from Ernst & Young LLP, which shall be in form and substance reasonably
satisfactory to Plexus and shall contain information concerning the financial
condition of SeaMED, dated the Closing Date, similar to the letter described in
Section 3.10 of this Agreement.
7.9 Pooling Opinion. Plexus shall have received an opinion from
PricewaterhouseCoopers LLP to the effect that the Merger qualifies for
pooling-of-interests accounting treatment if consummated in accordance with this
Agreement, and such related opinions from Ernst & Young, LLP as may be required
in connection therewith.
-39-
<PAGE> 46
7.10 Affiliate Letters. Plexus shall have received an Affiliate
Letter from each Person who is an Affiliate of either Plexus or SeaMED.
7.11 Plexus Stock Value. The Plexus Stock Value shall equal or exceed
$27.00.
7.12 Employment Agreements. Each of W. Robert Berg, Donald Rich,
Edgar F. Rampy, Erik Hagstrom and Marcia Page shall have executed and delivered
an Employment Agreement in the form of Exhibit C to this Agreement.
7.13 SeaMED Rights and Approval. SeaMED and its Board of Directors
shall have taken all action necessary to (i) redeem, conditioned upon the
occurrence of the Closing, all rights to acquire any SeaMED securities pursuant
to the SeaMED Rights; and (ii) approve the Merger under applicable provisions of
WBCA (including without limitation WBCA 23B.19.040).
7.14 Dissenters. As of the Closing, shares of SeaMED Common Stock as
to which dissenters' rights are perfected shall represent not more than seven
and one-half percent (7 1/2%) of the voting power of all outstanding shares of
SeaMED Common Stock.
7.15 Consents. SeaMED and Plexus shall have obtained the consent of
all parties to Existing Contracts (where required by the applicable contract)
except where the failure to obtain such consent would not reasonably be expected
to have, individually or in the aggregate, a SeaMED Material Adverse Effect.
ARTICLE VIII
CONDITIONS PRECEDENT TO THE
OBLIGATIONS OF SEAMED
Each and every obligation of SeaMED to be performed on the Closing Date
shall be subject to the satisfaction prior to or at the Closing of the following
express conditions precedent:
8.1 Compliance with Agreement. Plexus and Acquisition shall have
performed and complied in all respects with all of their obligations under this
Agreement which are to be performed or complied with by them prior to or on the
Closing Date, except where the failure to perform or comply, individually or in
the aggregate, would not or would not be reasonably likely to result in a Plexus
Material Adverse Effect.
8.2 No Litigation. No suit, action or other proceeding shall be
pending before any court in which the consummation of the transactions
contemplated by this Agreement is restrained or enjoined.
8.3 Representations and Warranties of Plexus and Acquisition. The
representations and warranties made by Plexus and Acquisition in this Agreement
shall be true and correct in all respects when made and as of the Closing Date
with the same force and effect as though such
-40-
<PAGE> 47
representations and warranties had been made on the Closing Date, except where
the effect of any breaches of the representations and warranties of Plexus and
Acquisition made in this Agreement, individually or in the aggregate, would not
or would not be reasonably likely to result in a Plexus Material Adverse Effect.
8.4 No Plexus Material Adverse Effect. During the period from the
date of this Agreement to the Closing Date there shall not have occurred, and be
continuing on the Closing Date, any Plexus Material Adverse Effect.
8.5 Approval of SeaMED Shareholders; Articles of Merger. This
Agreement, the Merger and the other transactions contemplated by this Agreement
shall have received the requisite approval and authorization of the SeaMED
Shareholders. The Articles of Merger shall have been executed and delivered by
Acquisition.
8.6 Closing Certificate. Plexus shall have delivered to SeaMED a
certificate signed on behalf of Plexus by the Chief Executive Officer and Chief
Financial Officer of Plexus, dated the Closing Date, to the effect that, to the
best of such officers' knowledge, the conditions set forth in Sections 8.1 and
8.3 of this Agreement have been satisfied.
8.7 Governmental Approvals.
(a) Registration Statement. The Registration Statement shall
have been declared effective under the Securities Act and shall not be the
subject of any stop order or proceedings to effect a stop order. The Plexus
Common Stock issuable pursuant to the Merger shall have been registered or shall
be exempt from registration or qualification under applicable state "blue sky"
or securities Laws.
(b) HSR Act. All necessary requirements of the HSR Act shall
have been complied with and any "waiting periods" applicable to the Merger and
to the transactions described in this Agreement which are imposed by the HSR Act
shall have expired prior to the Closing Date or shall have been terminated by
the appropriate agency.
8.8 Tax Opinion. SeaMED shall have received an opinion of Preston
Gates & Ellis LLP, counsel to SeaMED, to the effect that the Merger will be
treated for federal income tax purposes as a reorganization within the meaning
of Section 368(a) of the Code, and that Plexus, Acquisition and SeaMED will each
be a party to that reorganization within the meaning of Section 368(b) of the
Code, dated on or about the date that is two (2) business days prior to the date
the Proxy Statement is first mailed to SeaMED Shareholders, and such opinion
shall not have been withdrawn or modified in any material respect as of the
Closing Date and the Effective Time of Merger. In rendering such opinion, such
counsel may require and rely upon representations contained in certificates of
SeaMED, Plexus and Acquisition.
8.9 Accountant Letter. SeaMED shall have received a copy of a letter
from PricewaterhouseCoopers LLP, which shall be in form and substance reasonably
satisfactory to SeaMED and shall contain information concerning the financial
condition of Plexus, dated the Closing Date, similar to the letter described in
Section 3.11 of this Agreement.
-41-
<PAGE> 48
8.10 Plexus Stock Value. The Plexus Stock Value shall equal or exceed
$27.00.
ARTICLE IX
TERMINATION; MISCELLANEOUS
9.1 Termination. This Agreement may be terminated and the
transactions contemplated by this Agreement may be abandoned at any time prior
to the Closing (whether before or after approval of this Agreement by the SeaMED
Shareholders), as follows:
(a) by mutual written agreement of Plexus and SeaMED, duly
authorized by the Boards of Directors of Plexus and SeaMED;
(b) by either Plexus or SeaMED by written notice to the
other party if: (i) any court of competent jurisdiction shall have issued an
order, judgment or decree permanently restraining, enjoining or otherwise
prohibiting the Merger and such order, judgment or decree shall have become
final and nonappealable; or (ii) if the Effective Time of Merger has not
occurred on or before October 31, 1999, provided, however, that the right to
terminate this Agreement under this Section 9.1(b)(ii) of this Agreement shall
not be available to any party whose failure to fulfill any obligation under this
Agreement has been the cause of, or resulted in, the failure of the Effective
Time of Merger to occur on or before that date;
(c) by Plexus by written notice to SeaMED if: (i) there
exists one or more breaches of the representations and warranties of SeaMED made
in this Agreement as of the date of this Agreement (as modified by the
Disclosure Schedule as of the date of this Agreement, but prior to any amendment
of the Disclosure Schedule after the date of this Agreement) which breaches,
individually or in the aggregate, would or would be reasonably likely to result
in a SeaMED Material Adverse Effect and such breaches shall not have been
remedied within twenty (20) calendar days after receipt by SeaMED of written
notice from Plexus specifying the nature of such breaches and requesting that
they be remedied; (ii) SeaMED shall have failed to perform and comply in all
respects with its agreements and covenants contained in Sections 6.10 and 6.11
of this Agreement; (iii) SeaMED shall have failed to perform and comply in all
respects with all of its other agreements and covenants contained in this
Agreement and such failures to perform or comply, individually or in the
aggregate, would or would be reasonably likely to result in a SeaMED Material
Adverse Effect and such failures to perform or comply shall not have been
remedied within twenty (20) calendar days after receipt by SeaMED of written
notice from Plexus specifying the nature of such failures to perform or comply
and requesting that they be remedied; (iv) SeaMED shall have convened the SeaMED
Special Meeting to vote upon the Merger and the transactions described in this
Agreement and such vote does not receive the requisite vote of the SeaMED
Shareholders for such proposal; (v) the Board of Directors of SeaMED or any
committee thereof: (A) shall withdraw or modify in any manner adverse to Plexus
its approval or recommendation of this Agreement or the Merger, (B) shall fail
to reaffirm such approval or recommendation upon the reasonable request of
Plexus, or (C) shall approve or recommend any Other Transaction; (vi) SeaMED or
any of the other persons or entities described in Section 3.9.3 shall take any
of the actions that would be proscribed by Section 3.9.3; (vii) SeaMED shall
have agreed to an Other Transaction or a Takeover Proposal; or (viii)
-42-
<PAGE> 49
SeaMED shall have terminated the Rights Agreement, redeemed the SeaMED Rights
(except as otherwise required by this Agreement) or approved any Other Proposal
as a permitted offer under the Rights Agreement; and
(d) by SeaMED by written notice to Plexus if: (i) there
exists one or more breaches of the representations and warranties of Plexus made
in this Agreement as of the date of this Agreement which breaches, individually
or in the aggregate, would or would be reasonably likely to result in a Plexus
Material Adverse Effect and such breaches shall not have been remedied within
twenty (20) calendar days after receipt by Plexus of written notice from SeaMED
specifying the nature of such breaches and requesting that they be remedied;
(ii) Plexus shall have failed to perform and comply in all respects with all of
its agreements and covenants contained in this Agreement and such failures to
perform or comply, individually or in the aggregate, would or would be
reasonably likely to result in a Plexus Material Adverse Effect and such
failures to perform or comply shall not have been remedied within twenty (20)
calendar days after receipt by Plexus of written notice from SeaMED specifying
the nature of such failures to perform or comply and requesting that they be
remedied; (iii) SeaMED shall have convened the SeaMED Special Meeting to vote
upon the Merger and the transactions described in this Agreement and such vote
does not receive the requisite vote of the SeaMED Shareholders for such
proposal; or (iv) pursuant to Section 3.9(d) of this Agreement;
9.2 Rights on Termination; Waiver. If this Agreement is terminated
pursuant to Section 9.1 of this Agreement, all further obligations of the
parties under or pursuant to this Agreement shall terminate without further
liability of any party (including its directors, officers, employees, agents,
legal, accounting or financial advisors or other representatives) to the others,
provided that: (a) the obligations of Plexus and Acquisition contained in
Sections 3.4(c), 9.2 and 9.5 of this Agreement shall survive any such
termination; (b) the obligations of SeaMED contained in Sections 3.4(c), 3.9(e),
9.2 and 9.5 of this Agreement shall survive any such termination; and (c) except
as provided in Section 3.9(e), each party to this Agreement shall retain any and
all remedies which it may have for breach of contract provided by Law based on
another party's willful failure to comply with the terms of this Agreement. If
any of the conditions set forth in Article VII of this Agreement have not been
satisfied, Plexus may nevertheless elect to proceed with the consummation of the
transactions contemplated by this Agreement and if any of the conditions set
forth in Article VIII of this Agreement have not been satisfied, SeaMED may
nevertheless elect to proceed with the consummation of the transactions
contemplated by this Agreement. Any such election to proceed shall be evidenced
by a certificate signed on behalf of the waiving party by an officer of that
party.
9.3 Survival of Representations, Warranties and Covenants. All
representations, warranties and covenants of the parties contained in this
Agreement (other than the covenants contained in Sections 2.8, 2.9, 2.12, 3.14,
3.17, 3.18, 3.19, 3.20, 9.3, 9.6, 9.12 and 9.14 of this Agreement) or made
pursuant to this Agreement shall terminate and be of no further force and effect
at the Effective Time of Merger and none of the parties shall have any liability
or obligation with respect thereto.
9.4 Entire Agreement; Amendment. This Agreement and the documents
referred to in this Agreement and required to be delivered pursuant to this
Agreement constitute the entire
-43-
<PAGE> 50
agreement among the parties pertaining to the subject matter of this Agreement,
and supersede all prior and contemporaneous agreements, understandings,
negotiations and discussions of the parties, whether oral or written, other than
the Confidentiality Agreement, and there are no warranties, representations or
other agreements between the parties in connection with the subject matter of
this Agreement, except as specifically set forth in this Agreement and in the
Confidentiality Agreement. EACH PARTY HERETO AGREES THAT, EXCEPT FOR THE
REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS AGREEMENT OR IN THE
CONFIDENTIALITY AGREEMENT, NO PARTY MAKES ANY OTHER REPRESENTATIONS OR
WARRANTIES, AND EACH HEREBY DISCLAIMS ANY OTHER REPRESENTATIONS OR WARRANTIES
MADE BY ITSELF OR ANY OF ITS OFFICERS, DIRECTORS, EMPLOYEES, AGENTS, FINANCIAL
AND LEGAL ADVISORS OR OTHER REPRESENTATIVES, WITH RESPECT TO THE EXECUTION AND
DELIVERY OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY,
NOTWITHSTANDING THE DELIVERY OR DISCLOSURE TO THE OTHER PARTIES OR TO THE
REPRESENTATIVES OF THE OTHER PARTIES OF ANY DOCUMENTATION OR OTHER INFORMATION
WITH RESPECT TO ANY ONE OR MORE OF THE FOREGOING. This Agreement may be amended
by the parties at any time before or after approval of this Agreement by the
SeaMED Shareholders, except that after such approval, no amendment shall be made
without the further approval of the SeaMED Shareholders if any such amendment:
(a) reduces the Exchange Rate; or (b) materially adversely affects the rights of
the SeaMED Shareholders. No amendment, supplement, modification, waiver or
termination of this Agreement shall be binding unless executed in writing by
Plexus, SeaMED and Acquisition. No waiver of any of the provisions of this
Agreement shall be deemed or shall constitute a waiver of any other provision of
this Agreement, whether or not similar, nor shall such waiver constitute a
continuing waiver unless otherwise expressly provided.
9.5 Expenses. All costs and expenses incurred in connection with
this Agreement and the transactions contemplated by this Agreement shall be paid
by the party incurring such expenses, except that: (a) Plexus shall pay the
filing fee relating to the filing required by the HSR Act; and (b) those
expenses incurred in connection with printing the Proxy Statement and
Registration Statement, as well as the filing fee relating thereto, shall be
shared equally by SeaMED, on the one hand, and Plexus, on the other hand.
9.6 Governing Law. This Agreement shall be construed and interpreted
according to the Laws of the State of Wisconsin, except to the extent that the
WBCA applies to procedures for effecting the Merger or to actions taken or
required to be taken by SeaMED's Board of Directors or shareholders.
9.7 Assignment. Prior to the Effective Time of Merger, this
Agreement shall not be assigned by any party to this Agreement except with the
prior written consent of the other parties to this Agreement.
9.8 Notices. All communications or notices required or permitted by
this Agreement shall be in writing and shall be deemed to have been given at the
earlier of the date when actually delivered to an officer of a party by personal
delivery or telephonic facsimile transmission
-44-
<PAGE> 51
(receipt electronically confirmed) or when deposited in the United States mail,
certified or registered mail, postage prepaid, return receipt requested, and
addressed as follows, unless and until any of such parties notifies the others
in accordance with this Section of a change of address:
If to Plexus or Acquisition: Plexus Corp.
Attention: Joseph D. Kaufman
55 Jewelers Park Drive
P.O. Box 156
Neenah WI 54956
Fax No.: 920/751-3234
with a copy to: Quarles & Brady LLP
Attention: Kenneth V. Hallett
411 E. Wisconsin Avenue
Milwaukee, WI 53202-4497
Fax No: 414/271-3552
If to SeaMED: SeaMED Corporation
Attention: W. Robert Berg
14500 NE 87th Street
Redmond, WA 98052
Fax No: 425/867-0622
with a copy to: Preston Gates & Ellis LLP
Attention: Mark R. Beatty
701 Fifth Avenue, Suite 5000
Seattle, WA 98104-7011
Fax No: 206/623-7022
9.9 Counterparts; Headings. This Agreement may be executed in
several counterparts, each of which shall be deemed an original, but such
counterparts shall together constitute but one and the same Agreement. The Table
of Contents and Article and Section headings in this Agreement are inserted for
convenience of reference only and shall not constitute a part hereof.
9.10 Interpretation. Unless the context requires otherwise, all words
used in this Agreement in the singular number shall extend to and include the
plural, all words in the plural number shall extend to and include the singular,
and all words in any gender shall extend to and include all genders. The
language used in this Agreement shall be deemed to be language chosen by the
parties to this Agreement to express their mutual intent. In the event an
ambiguity or question of intent or interpretation arises concerning the language
of this Agreement, this Agreement shall be construed as if drafted jointly by
the parties to this Agreement and no presumption or burden of proof will arise
favoring or disfavoring any party to this Agreement by virtue of the authorship
of any of the provisions of this Agreement.
-45-
<PAGE> 52
9.11 Severability. If any provision, clause, or part of this
Agreement, or the application thereof under certain circumstances, is held
invalid, the remainder of this Agreement, or the application of such provision,
clause or part under other circumstances, shall not be affected thereby unless
such invalidity materially impairs the ability of the parties to consummate the
transactions contemplated by this Agreement.
9.12 No Reliance. Except for the parties to this Agreement, any
assignees permitted by Section 9.7 of this Agreement and as described in Section
3.14 and Section 3.20 of this Agreement: (a) no Person is entitled to rely on
any of the representations, warranties and agreements of the parties contained
in this Agreement; and (b) the parties assume no liability to any Person because
of any reliance on the representations, warranties and agreements of the parties
contained in this Agreement.
9.13 Exhibits and Disclosure Schedule. All capitalized terms used in
any Exhibit to this Agreement or in the Disclosure Schedule shall have the
definitions specified in this Agreement.
9.14 Further Assurances. If, at any time after the Effective Time of
Merger, any further action is necessary or desirable to carry out the purposes
of this Agreement and to vest the Surviving Corporation with full right, title
and possession to all assets, properties, rights, privileges, powers and
franchises of either Acquisition or SeaMED, the officers of the Surviving
Corporation are fully authorized to take any such action in the name of
Acquisition or SeaMED.
IN WITNESS WHEREOF, the parties have caused this Agreement and Plan of
Merger to be duly executed as of the day and year first above written.
PLEXUS CORP.
By_______________________________________
John L. Nussbaum, President and
Chief Operating Officer
SEAMED CORPORATION
By_______________________________________
W. Robert Berg, President and Chief
Executive Officer
PS ACQUISITION CORP.
By_______________________________________
John L. Nussbaum, President
-46-
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> SEP-30-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> MAR-31-1999
<EXCHANGE-RATE> 1
<CASH> 33,181
<SECURITIES> 0
<RECEIVABLES> 52,023
<ALLOWANCES> 630
<INVENTORY> 41,700
<CURRENT-ASSETS> 135,410
<PP&E> 57,180
<DEPRECIATION> 33,928
<TOTAL-ASSETS> 159,835
<CURRENT-LIABILITIES> 51,814
<BONDS> 0
0
0
<COMMON> 151
<OTHER-SE> 106,127
<TOTAL-LIABILITY-AND-EQUITY> 159,835
<SALES> 103,388
<TOTAL-REVENUES> 103,388
<CGS> 88,177
<TOTAL-COSTS> 88,177
<OTHER-EXPENSES> 4,924
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 2
<INCOME-PRETAX> 10,285
<INCOME-TAX> 4,113
<INCOME-CONTINUING> 6,172
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 6,172
<EPS-PRIMARY> 0.41
<EPS-DILUTED> 0.38
</TABLE>
